Reports

Lilly reported 38% year-over-year revenue growth to $15.56 billion and a 92% increase in EPS to $6.29, driven by robust sales of Zepbound and Mounjaro, expanded margins, and raised full-year guidance.

• Worldwide revenue grew 38% to $15.56 billion
• Volume increased 42%, offsetting a 6% price decline

Sony posted a solid Q1 FY2025 with increased revenue and operating income, supported by robust performance in its gaming and imaging & sensing segments.

• Revenue rose to ¥2.6216 trillion, up from ¥2.5654 trillion in Q1 FY2024.
• Operating income surged to ¥340 billion, a 36% increase year-on-year.

Gilead Sciences delivered a strong second quarter in 2025, with total revenue reaching $7.1 billion, a 2% increase from the previous year. This growth was primarily fueled by robust sales in HIV products, particularly Biktarvy and Descovy, as well as contributions from Livdelzi and Trodelvy. Diluted EPS rose to $1.56, up from $1.29 in Q2 2024, largely due to net unrealized gains on securities and higher product sales, despite an IPR&D impairment charge and increased R&D expenses. The company also increased its full-year revenue and earnings guidance.

• Total second quarter 2025 revenue increased 2% year-over-year to $7.1 billion.
• Diluted EPS for Q2 2025 was $1.56, an increase from $1.29 in Q2 2024.

ConocoPhillips delivered $14.74B in revenue and $1.97B in net income during Q2 2025, supported by strong asset sales and cost discipline across operations.

• Net income reached $1.97 billion for the quarter.
• Adjusted EPS came in at $1.41 per share.

Brookfield delivered a net income of $1.055 billion and revenues of $18.083 billion in Q2 2025. Distributable earnings before realizations rose to $1.253 billion, driven by strength in asset management, wealth solutions, and operating businesses. EPS came in at $0.15 and adjusted EPS at $0.88.

• Net income rebounded to $1.055 billion from a loss of $285 million in Q2 2024.
• Revenue for the quarter totaled $18.083 billion.

Constellation Energy delivered strong financial performance in Q2 2025, with adjusted EPS rising to $1.91 and GAAP EPS at $2.67. Operating income reached $951 million, supported by increased revenue and favorable market conditions. The company also repurchased $400 million in shares and announced a significant 20-year deal with Meta.

• Reported GAAP EPS of $2.67 and adjusted EPS of $1.91 in Q2 2025.
• Generated $6.101 billion in revenue with $951 million in operating income.

Parker-Hannifin delivered an outstanding performance in the fourth quarter of fiscal year 2025, achieving record sales of $5.2 billion and a record adjusted EPS of $7.69. The company saw significant increases in net income and segment operating margin, contributing to a record-breaking fiscal year across multiple key metrics including safety, engagement, earnings per share, margins, and cash flow. The Aerospace Systems segment was a strong performer with significant organic sales growth and record adjusted operating margin, while the Diversified Industrial segment achieved record adjusted operating margins in both North America and International businesses.

• Record sales of $5.2 billion were achieved in Q4 FY25, with organic sales growth of 2%.
• Diluted EPS increased by 19% to $7.15, and adjusted diluted EPS rose by 14% to a record $7.69.

CNRL delivered $2.5 billion in net income and adjusted net earnings of $1.5 billion. Production averaged over 1.42 million BOE/d, with cost efficiencies achieved across operations. Despite a planned turnaround at AOSP, the company executed strong capital discipline and continued to return significant value to shareholders.

• Net income reached $2.5 billion with EPS of $1.17.
• Adjusted net earnings were $1.5 billion or $0.71 per share.

The company delivered strong second-quarter results, with higher sales in Software & Services and strong backlog driven by robust order activity. Motorola Solutions also raised its full-year revenue and EPS outlook.

• Revenue grew to $2.765 billion, driven by Software & Services segment growth.
• GAAP EPS was $3.04; Non-GAAP EPS was $3.57.

Vistra posted a strong Q2 2025 with $4.25 billion in revenue and $327 million in net income. The company reaffirmed its full-year guidance and announced the acquisition of natural gas assets and a 20-year license extension for the Perry Nuclear Power Plant.

• Generated $327 million in GAAP net income and $1.349 billion in adjusted EBITDA.
• Reported $4.25 billion in operating revenue for Q2 2025.

Monster Beverage Corporation achieved record quarterly net sales of $2.11 billion in Q2 2025, an 11.1% increase year-over-year. Operating income rose by 19.8% to $631.6 million, and diluted EPS increased by 21.1% to $0.50 per share, demonstrating robust growth driven by strong brand performance and product innovation.

• Record quarterly net sales surpassed $2.0 billion for the first time, reaching $2.11 billion.
• Operating income increased significantly by 19.8% to $631.6 million.

Cheniere delivered a strong second quarter in 2025, with significant increases in revenue and net income compared to the prior year. The company also made a positive Final Investment Decision for the CCL Midscale Trains 8 & 9 Project and achieved substantial completion of Train 2 of the CCL Stage 3 Project, demonstrating continued growth and operational execution.

• Revenues increased by 43% to $4.6 billion in Q2 2025 compared to Q2 2024.
• Net income attributable to Cheniere surged by 85% to $1.626 billion in Q2 2025.

Atlassian closed out fiscal year 2025 with over $5.2 billion in revenue and $1.4 billion in free cash flow, driven by strong cloud revenue growth. The company reported a 22% year-over-year increase in total revenue for Q4, reaching $1.384 billion, and a non-GAAP operating margin of 24%.

• Total revenue for Q4 FY25 reached $1.384 billion, marking a 22% increase year-over-year.
• Subscription revenue for Q4 FY25 was $1.313 billion, up 23% compared to the previous year.

Petrobras posted solid results in Q2 2025, with net income of $4.76 billion and EPS of $0.83 per ADS. Revenue reached $21.04 billion, while operating income was $5.35 billion, supported by gains in exploration and production and improved financial results.

• Net income for the quarter was $4.76 billion, a significant improvement from a loss in Q2 2024.
• Revenue totaled $21.04 billion, reflecting strong domestic and export performance.

BD delivered a robust performance in the third quarter of fiscal 2025, with total revenues reaching $5.51 billion, marking a 10.4% increase year-over-year. Both GAAP and adjusted diluted EPS saw substantial growth, reaching $2.00 and $3.68 respectively. The company's operating income surged by 46.6%, reflecting strong operational efficiency and the positive impact of BD Excellence. BD also raised its full-year adjusted diluted EPS guidance, underscoring confidence in its continued financial performance.

• Total revenues for Q3 fiscal 2025 increased by 10.4% to $5.509 billion, compared to $4.990 billion in the prior year.
• GAAP diluted EPS grew by 19.0% to $2.00, while adjusted diluted EPS increased by 5.1% to $3.68.

In Q2 2025, Sempra delivered $461 million in GAAP net income and $583 million in adjusted earnings. Revenue was steady at $3.0 billion. EPS came in at $0.71 and adjusted EPS at $0.89. Segment contributions were led by Sempra California and Sempra Texas, while Sempra Infrastructure saw a significant year-over-year decline in contribution.

• GAAP net income of $461 million, down from $713 million in Q2 2024.
• Adjusted earnings rose to $583 million with EPS flat at $0.89 YoY.

Datadog delivered 28% year-over-year revenue growth in Q2 2025, achieved $165 million in free cash flow, and reported a modest profit, all while launching over 125 new features and products.

• Revenue reached $826.76 million, up 28% YoY
• GAAP EPS was $0.01 and non-GAAP EPS was $0.46

Take-Two exceeded expectations on net bookings and revenue in Q1 FY26, driven by strong mobile and franchise title performance, although it still posted a GAAP net loss.

• Net Bookings reached $1.423 billion, exceeding guidance
• GAAP Net Revenue came in at $1.504 billion

Kenvue experienced a decline in net sales and organic sales in Q2 2025, primarily due to unfavorable value realization and volume decline. Despite this, the company reported a substantial increase in net income and diluted EPS compared to the prior year, largely due to the absence of significant asset impairment charges that affected the previous year's results. Gross profit margin and adjusted gross profit margin contracted, while operating income margin saw a significant improvement.

• Net sales decreased by 4.0% to $3,839 million, primarily driven by a 4.2% organic sales decline.
• Diluted earnings per share increased significantly to $0.22 from $0.03 in the prior year, while Adjusted diluted earnings per share decreased to $0.29 from $0.32.

Microchip Technology began fiscal 2026 with a sequential revenue increase of 10.8% and beat its own EPS and revenue guidance. Despite a GAAP net loss due to non-cash charges and preferred dividends, the company demonstrated operational improvements and strong free cash flow.

• Revenue came in at $1.0755 billion, up 10.8% sequentially.
• GAAP EPS was -$0.09, while non-GAAP EPS reached $0.27.

Targa Resources Corp. delivered a strong second quarter in 2025, with net income attributable to Targa Resources Corp. more than doubling year-over-year to $629.1 million. Adjusted EBITDA also saw a significant increase, rising 18% to $1,163.0 million, driven by record Permian and NGL transportation volumes. The company continued its share repurchase program and provided an updated outlook for full-year 2025 adjusted EBITDA and growth capital expenditures.

• Net income attributable to Targa Resources Corp. for Q2 2025 was $629.1 million, a significant increase from $298.5 million in Q2 2024.
• Adjusted EBITDA reached $1,163.0 million in Q2 2025, an 18% increase compared to $984.3 million in Q2 2024, driven by record Permian and NGL transportation volumes.

Con Edison reported a strong Q2 2025 with GAAP EPS of $0.68 and adjusted EPS of $0.67, driven by increased electric rate base and cost recoveries. The company reaffirmed its full-year adjusted EPS guidance and highlighted strategic progress on grid modernization and clean energy investments.

• GAAP EPS was $0.68, up from $0.58 in Q2 2024.
• Non-GAAP EPS was $0.67, compared to $0.59 in Q2 2024.

Live Nation delivered record revenue of $7.01 billion and grew operating income to $486.7 million in Q2 2025, driven by strong global demand for concerts and robust growth across ticketing and sponsorships.

• Revenue reached $7.01 billion, driven by record concert ticket sales and onsite spending
• Global attendance grew 14% to 44 million fans, with international markets leading the surge

Martin Marietta delivered a robust second-quarter performance in 2025, achieving record aggregates revenues and profitability, along with record Adjusted EBITDA. The company's Magnesia Specialties business also saw record revenues and gross profit. This strong performance led to an increase in the full-year 2025 Adjusted EBITDA guidance.

• Revenues increased by 3% to $1.811 billion, and net earnings attributable to Martin Marietta rose by 12% to $328 million.
• Aggregates product line achieved record profitability, with average selling price per ton increasing by 7% to $23.21, despite a slight 0.6% decrease in shipments.

WBD posted $9.81B in revenue and $1.58B in net income, as Studios revenue surged 55% and streaming added 3.4M subscribers. Adjusted EBITDA rose 9% year-over-year to $1.95B.

• Studios revenue increased 55% YoY, fueled by strong box office from multiple blockbuster films.
• Streaming subscribers grew by 3.4M to reach 125.7M globally.

Liberty Formula One delivered an excellent performance in Q2 2025, with total revenue reaching $1.341 billion, a substantial increase from the previous year. The company saw significant growth in operating income and Adjusted OIBDA, primarily due to an additional race in the quarter and strong commercial momentum, including new partnerships and increased fan engagement. The acquisition of MotoGP was completed post-quarter, signaling future expansion.

• Total Formula One Group revenue increased by 35.7% to $1.341 billion in Q2 2025, compared to $988 million in Q2 2024.
• Operating income for the Formula One Group surged by 374.6% to $280 million, up from $59 million in the prior year period.

GoDaddy reported $1.22 billion in revenue for Q2 2025, driven by strong performance in Applications & Commerce and improved operating margins. Free cash flow rose to $392 million while NEBITDA margin expanded to 31.3%.

• Revenue grew 8% YoY to $1.22 billion, led by strength in A&C segment
• Applications & Commerce revenue increased 14% to $464 million

Natera delivered outstanding results in the second quarter of 2025, with total revenues increasing by 32.2% year-over-year to $546.6 million. This growth was primarily fueled by a 32.3% increase in product revenues and higher test volumes. Despite increased operating expenses, the company improved its gross margin and ended the quarter with over $1 billion in cash and equivalents.

• Total revenues for Q2 2025 reached $546.6 million, a 32.2% increase from Q2 2024.
• Product revenues were the primary driver of growth, rising 32.3% to $544.4 million.

Pinterest delivered a robust second quarter in 2025, achieving 17% revenue growth year-over-year to $998 million and reaching an all-time high of 578 million global monthly active users, an 11% increase. The company also reported a GAAP net income of $39 million and a non-GAAP net income of $228 million, alongside strong free cash flow.

• Revenue increased by 17% year-over-year to $998 million, both on a reported and constant currency basis.
• Global Monthly Active Users (MAUs) reached a record 578 million, up 11% year-over-year.

Restaurant Brands International (RBI) delivered a solid second quarter in 2025, with consolidated system-wide sales growing 5.3% year-over-year and comparable sales accelerating to 2.4%. The company saw strong performance from Tim Hortons Canada and Burger King International, and remains on track to achieve its 8%+ organic Adjusted Operating Income growth target for 2025.

• Consolidated system-wide sales increased by 5.3% year-over-year, driven by strong international growth.
• Comparable sales accelerated to 2.4%, with notable contributions from Burger King International (4.1%) and Tim Hortons Canada (3.6%).

Insulet delivered robust second quarter 2025 results, with total revenue increasing by 32.9% year-over-year to $649.1 million, driven by strong performance in both U.S. and International Omnipod segments. The company also saw significant improvements in gross margin, operating income, and adjusted EBITDA, while raising its full-year revenue and adjusted operating margin guidance.

• Total revenue for Q2 2025 reached $649.1 million, marking a 32.9% increase year-over-year, surpassing the company's guidance.
• Omnipod revenue grew by 33.0% to $639.0 million, with strong contributions from both U.S. Omnipod (up 28.7%) and International Omnipod (up 45.0%).

Expedia Group delivered a strong second quarter in 2025, surpassing revenue and earnings expectations. The company saw continued strength in its B2B and Advertising segments, leading to a 6% year-over-year revenue increase and a 21% increase in Adjusted EPS. Based on this performance, Expedia Group has raised its full-year guidance.

• Expedia Group exceeded its Q2 2025 top and bottom-line expectations, with revenue growing 6% and gross bookings increasing 5% year-over-year.
• Adjusted EBITDA increased by 16% and Adjusted EPS by 21% year-over-year, indicating strong profitability and margin expansion.

Insmed delivered $107.4 million in revenue for Q2 2025, reflecting 19% year-over-year growth, with ARIKAYCE sales increasing across all regions. However, the company posted a net loss of $321.7 million due to rising R&D and SG&A expenses.

• Total revenue reached $107.4 million, up from $90.3 million in Q2 2024.
• ARIKAYCE net sales increased in all key geographies, led by Japan with 45% growth.

Gen Digital delivered a robust Q1 FY26 with double-digit revenue growth and strong non-GAAP earnings, driven by strong performance in Cyber Safety and Trust-Based Solutions.

• Revenue grew 30% year-over-year to $1.257 billion.
• Non-GAAP EPS increased 20% year-over-year to $0.64.

Twilio reported strong second-quarter results, with total revenue reaching $1.23 billion, marking a 13% year-over-year increase. The company achieved GAAP income from operations of $37 million and non-GAAP income from operations of $221 million, significantly improving profitability. Non-GAAP diluted EPS was $1.19, exceeding prior year's performance. Free cash flow also saw a substantial increase to $263.5 million.

• Total revenue for Q2 2025 was $1.23 billion, representing a 13% year-over-year increase.
• GAAP income from operations improved significantly to $37 million, compared to a loss in the prior year.

US Foods delivered a robust performance in the second quarter of fiscal year 2025, with net sales growing 3.8% to $10.1 billion, net income increasing 13.1% to $224 million, and adjusted EBITDA rising 12.1% to $548 million. The company also saw significant growth in diluted EPS and adjusted diluted EPS, and successfully reduced its net leverage ratio.

• Net sales increased 3.8% to $10.1 billion, driven by case volume growth and food cost inflation.
• Net income grew 13.1% to $224 million, and Adjusted EBITDA increased 12.1% to $548 million, reflecting strong operational execution and margin expansion.

Erie Indemnity posted strong financial results for Q2 2025, with higher net income, increased management fee revenue, and improved investment income compared to the prior year.

• Net income rose to $174.7 million, up from $163.9 million in Q2 2024.
• EPS increased to $3.34 per diluted share.

Ralph Lauren reported strong Q1 FY2026 results, with 14% revenue growth and a 40% increase in adjusted EPS. Growth was broad-based across geographies, and the company raised its full-year revenue and margin guidance.

• Revenue grew 14% year-over-year to $1.72 billion, driven by strong performance in all geographies.
• Adjusted EPS rose 40% to $3.77, exceeding analyst expectations.

Alliant Energy delivered a solid performance in Q2 2025 with EPS of $0.68 and revenue of $961 million, supported by favorable rate base investments and weather-related demand increases.

• GAAP EPS for Q2 2025 was $0.68, up from $0.34 in Q2 2024
• Net income rose to $174 million, doubling from $87 million in the same period last year

In Q2 2025, YPF generated 4641000000 in total revenue, delivered adjusted EBITDA of 1124000000, and reported net income of 58000000. The quarter was marked by stable production and a negative free cash flow of 365000000 amid lower international crude prices.

• Total revenues were 4641000000 in Q2 2025, down 6% year-over-year. :contentReference[oaicite:1]{index=1}
• Net income was 58000000, reversing the prior quarter’s loss. :contentReference[oaicite:2]{index=2}

Rocket Lab achieved record quarterly revenue of $144 million, driven by strong space systems growth and five Electron launches, while also expanding gross margins by 650 basis points YoY.

• Revenue reached $144 million, a 36% increase YoY
• Five successful Electron launches executed in Q2

Warner Music Group saw revenue growth across Recorded Music and Music Publishing, but foreign exchange losses and higher restructuring costs led to a quarterly net loss.

• Revenue increased to $1.689 billion, driven by growth in digital and licensing segments.
• Net loss of $16 million primarily due to FX losses and restructuring charges.

Genmab delivered robust Q2 2025 results with 19% year-over-year revenue growth. The performance was fueled by strong royalty revenues from DARZALEX and Kesimpta, as well as increased net product sales of EPKINLY. Despite higher costs, operating profit and net income both rose significantly, reflecting effective commercialization strategies and pipeline expansion.

• Revenue rose 19% year-over-year to $925 million in Q2 2025.
• EPS increased to $5.44 from $3.15 in Q2 2024.

Texas Roadhouse delivered a strong second quarter in 2025, with total revenue increasing by 12.7% and diluted EPS up by 4.0%. The company saw comparable restaurant sales growth and an increase in restaurant margin dollars, despite inflationary pressures on commodities and labor.

• Total revenue for the quarter reached $1,512,054,000, a 12.7% increase year-over-year.
• Diluted earnings per share rose to $1.86, up 4.0% from the prior year.

SharkNinja reported strong financial results for the second quarter of 2025, with net sales increasing by 15.7% to $1.44 billion and Adjusted EBITDA growing by approximately 33%. The company's performance was bolstered by growth in Food Preparation, Cleaning, and Beauty and Home Environment Appliances, alongside robust domestic and international sales increases. Cost optimization efforts also contributed to an improved gross margin.

• Net sales increased by 15.7% to $1,444.9 million, demonstrating strong top-line growth.
• Adjusted EBITDA surged by 33.2% to $223.4 million, indicating enhanced profitability.

In Q2 2025, Solventum achieved higher sales and maintained profitability despite margin pressures from higher operating costs and lower gross margins. The company saw positive organic sales growth in all segments, particularly MedSurg and Health Information Systems, and raised its full-year revenue and earnings guidance.

• Revenue grew 3.9% to $2.16 billion, with 2.8% organic growth.
• GAAP EPS was $0.51; non-GAAP EPS was $1.69.

Akamai reported strong second-quarter results with revenue of $1.043 billion, up 7% year-over-year, and non-GAAP EPS of $1.73, up 9%. The company saw significant growth in Cloud Infrastructure Services (30%) and Security revenue (11%), leading to increased full-year guidance.

• Total revenue reached $1.043 billion, marking a 7% increase year-over-year.
• Non-GAAP diluted EPS was $1.73, an increase of 9% compared to the prior year.

Celsius Holdings reported record revenue of $739.3 million in Q2 2025 driven by the April acquisition of Alani Nu, achieving $99.9 million in net income and $210.3 million in adjusted EBITDA, while U.S. retail share expanded to 17.3 percent.

• Record quarterly revenue of $739.3 million, driven by Alani Nu acquisition.
• Gross profit increased to $380.9 million with a 51.5 percent margin.

Doximity delivered a robust performance in Q1 Fiscal 2026, exceeding expectations with a 15% increase in total revenues to $145.9 million. The company demonstrated strong profitability, with net income rising to $53.3 million and non-GAAP net income reaching $71.9 million. Operating cash flow and free cash flow also saw substantial growth, increasing by 51% and 52% respectively, highlighting efficient operations and strong cash generation.

• Total revenues for Q1 Fiscal 2026 reached $145.9 million, marking a 15% increase year-over-year.
• Net income grew to $53.3 million, up from $41.4 million in the prior year, with a margin of 36.5%.

Ascendis Pharma delivered strong financial results in Q2 2025, with total revenue reaching €158.0 million, a substantial increase from the previous year, primarily due to the robust performance of YORVIPATH and SKYTROFA. The company also made significant strides in its clinical development, with TransCon CNP under FDA Priority Review and planned label expansions for SKYTROFA.

• Total revenue for Q2 2025 was €158.0 million, a significant increase from €36.0 million in Q2 2024.
• YORVIPATH revenue reached €103.0 million and SKYTROFA revenue was €50.7 million in Q2 2025.

Viatris delivered a strong second quarter in 2025, with total revenues exceeding expectations, reflecting the strength and resilience of its diversified global business. The company reported a significant improvement in U.S. GAAP net loss and diluted EPS compared to the prior year, while also reaffirming its full-year 2025 financial guidance ranges across all metrics.

• Total revenues for Q2 2025 were $3.5821 billion, exceeding expectations despite a reported 6% decrease year-over-year.
• The company significantly reduced its U.S. GAAP net loss to $(4.6) million in Q2 2025, a substantial improvement from $(326.4) million in Q2 2024.

MACOM Technology Solutions Holdings, Inc. announced robust financial results for its fiscal third quarter ended July 4, 2025, with revenue increasing by 32.3% year-over-year and GAAP net income more than doubling. The company also reported strong non-GAAP results, highlighting improved profitability and market momentum.

• Revenue for Q3 2025 reached $252.1 million, marking a 32.3% increase compared to the same period last year.
• GAAP net income significantly grew to $36.5 million, or $0.48 per diluted share, up from $19.9 million, or $0.27 per diluted share, in the prior year's fiscal third quarter.

Wynn Resorts posted $1.74B in revenue for Q2 2025, with EPS of $0.64 and Adjusted Property EBITDAR of $552.4M. Las Vegas achieved a record second-quarter EBITDAR, while Macau performance was pressured by VIP hold variance.

• Q2 2025 revenue reached $1.74B, up slightly from last year.
• Net income attributable to Wynn Resorts was $66.2M with diluted EPS of $0.64.

EPAM Systems, Inc. announced robust results for the second quarter ended June 30, 2025, with revenues reaching $1.35 billion, an 18.0% increase year-over-year. The company reported GAAP diluted EPS of $1.56 and non-GAAP diluted EPS of $2.77, demonstrating a return to consistent performance driven by deep engineering and AI-led solutions.

• EPAM achieved $1.35 billion in revenue for Q2 2025, marking an 18.0% year-over-year increase.
• GAAP diluted EPS was $1.56, while non-GAAP diluted EPS stood at $2.77.

Advanced Drainage Systems delivered strong results in the fiscal first quarter, with net sales increasing by 1.8% to $829.9 million. However, net income decreased by 11.2% to $144.1 million, and diluted EPS fell by 10.7% to $1.84. Adjusted EBITDA saw a modest increase of 1.0% to $278.2 million, with an Adjusted EBITDA margin of 33.5%. The company noted challenges from wet weather and elevated interest rates but highlighted strong execution by its teams, strategic investments, and the acquisition of River Valley Pipe.

• Net sales increased by 1.8% to $829.9 million, driven by acquisitions and growth in non-residential and residential construction.
• Net income decreased by 11.2% to $144.1 million, and diluted EPS fell by 10.7% to $1.84.

Dropbox delivered a strong second quarter in fiscal year 2025, with revenue of $625.7 million, a 1.4% decrease year-over-year. Despite the revenue dip, the company saw significant improvements in profitability, with GAAP net income rising to $125.6 million and Non-GAAP net income reaching $197.7 million. Operating margins also expanded, reflecting increased efficiency and progress on key product initiatives like Dash.

• Total revenue for Q2 2025 was $625.7 million, a 1.4% decrease year-over-year, but showed stability in its Core FSS business.
• GAAP net income increased to $125.6 million from $110.5 million in the prior year, and Non-GAAP net income rose to $197.7 million from $194.1 million.

Globus Medical delivered a robust performance in the second quarter of 2025, with worldwide net sales reaching $745.3 million, an 18.4% increase year-over-year. GAAP net income surged by 538.7% to $202.8 million, primarily due to a bargain purchase gain and a tax benefit. Diluted EPS was $1.49, significantly up from $0.23 in the prior year, while non-GAAP diluted EPS also increased to $0.86.

• Worldwide net sales increased by 18.4% to $745.3 million in Q2 2025, demonstrating strong top-line growth.
• GAAP net income for the quarter was $202.8 million, a substantial increase of 538.7% year-over-year, boosted by a bargain purchase gain and tax benefit.

Genpact delivered $1.254B in Q2 2025 revenue, up 6.6% year-over-year, with EPS of $0.75 and adjusted EPS of $0.88. Growth was fueled by a 9.7% increase in Data-Tech-AI revenues and a 17.3% surge in Advanced Technology Solutions, while Digital Operations rose 4.0%.

• Revenue reached $1.254B, up 6.6% year-over-year.
• Net income was $133M with diluted EPS of $0.75; adjusted EPS was $0.88.

Starwood Property Trust delivered a solid second quarter in 2025, with GAAP net income of $129.8 million and Distributable Earnings of $151.1 million. The company significantly surpassed its 2024 capital deployment, investing $3.2 billion in the quarter, and continued its strategic diversification, with commercial real estate lending now representing about half of its asset base. The acquisition of Fundamental Income Properties further strengthens its net lease real estate platform.

• Achieved GAAP earnings of $0.38 and Distributable Earnings (DE) of $0.43 per diluted share for Q2 2025.
• Invested $3.2 billion in the quarter, contributing to a total of $5.5 billion in the first six months, exceeding full-year 2024 capital deployment.

Elanco Animal Health delivered its eighth consecutive quarter of growth in Q2 2025, with revenue increasing by 5% year-over-year to $1,241 million, driven by 8% organic constant currency growth. The company reported a net income of $11 million and adjusted EPS of $0.26. Strong performance in Pet Health, particularly from new products, and increased volumes in Farm Animal segments contributed to the positive results. Elanco also improved its full-year financial outlook and net leverage ratio target.

• Achieved 8th consecutive quarter of growth with total revenue of $1,241 million, up 5% year-over-year, and 8% organic constant currency growth.
• Pet Health revenue increased by 11% to $643 million, with new products like Credelio Quattro, AdTab, and Zenrelia driving volume growth.

Kratos delivered strong second quarter 2025 results, with revenues increasing by 17.1% year-over-year to $351.5 million, driven by robust organic growth, particularly in the Kratos Government Solutions segment. Despite a decrease in GAAP net income and EPS, the company's Adjusted EBITDA remained solid, and it increased its full-year revenue and Adjusted EBITDA guidance, reflecting confidence in future performance and strategic market positioning.

• Second quarter 2025 revenues reached $351.5 million, marking a 17.1% increase over Q2 2024, with 15.2% organic growth.
• GAAP Net Income for Q2 2025 was $2.9 million ($0.02 EPS), while Adjusted EPS was $0.11.

Post Holdings delivered revenue growth and improved profitability in Q3 2025, supported by gains in Foodservice and Refrigerated Retail segments, partially offset by weakness in Post Consumer Brands. Adjusted EBITDA margin expanded, and the company raised its full-year guidance.

• Net sales reached $1.98 billion, up 1.9% from the prior year.
• Operating profit grew 15.5% to $234.6 million.

Millicom reported Q2 2025 revenue of $1.372 billion, net income of $676 million including $590 million from infrastructure transactions, adjusted EBITDA of $641 million (46.7% margin), and equity free cash flow of $218 million, with net leverage down to 2.18x.

• Revenue of $1.372 billion, down 5.9% year-on-year due to FX headwinds.
• Net income of $676 million, including $590 million net from infrastructure transactions.

MP Materials demonstrated strong performance in Q2 2025 with an 84% year-over-year revenue increase to $57.4 million, driven by higher production and sales of separated rare earth products. The company achieved record NdPr production and its second-highest REO production, while the Magnetics Segment began profitably ramping metal production and contributed significantly to revenue.

• Total revenue surged 84% year over year to $57.4 million, primarily due to increased sales of separated NdPr oxide and metal.
• Record NdPr production reached 597 metric tons, marking a 119% increase compared to the previous year.

Terreno Realty achieved $95.2 million in revenue and net income of $29.2 million for Q2 2025. Rental income was the primary contributor, with strong performance across all major geographic segments. Real estate occupancy remained high at 97.4%, and average base rent (ABR) continued to rise. The company maintained solid financial health and portfolio growth.

• Total revenue was $95.2 million, primarily from rental activities.
• Net income reached $29.2 million for the quarter.

Crocs, Inc. delivered a solid second quarter in 2025, with total revenues increasing by 3.4% to $1.149 billion. Despite a net loss of $492.282 million due to significant impairment charges, the company achieved a record gross profit of $708.836 million. Strong cash flow generation allowed for $133 million in share repurchases and $105 million in debt paydown, demonstrating effective capital management amidst a challenging operating environment.

• Total revenues increased by 3.4% year-over-year to $1.149 billion in Q2 2025.
• The company reported a net loss of $492.282 million, primarily due to $737 million in non-cash impairment charges related to the HEYDUDE brand.

Main Street Capital delivered a strong performance in Q2 2025, marked by an annualized return on equity of 17.1%, robust net investment income, and a record net asset value per share. The company's diversified investment strategies and cost-efficient operations contributed to these positive results, enabling increased dividends to shareholders.

• Net investment income reached $88.2 million, or $0.99 per share, showing a 5% increase from the prior year.
• Distributable net investment income was $94.3 million, or $1.06 per share, up 6% year-over-year.

In Q2 2025, Sezzle achieved total revenue of $98.7M, up 76% year-over-year, driven by higher transaction volumes and increased transaction-related revenue. Net income rose to $27.6M, while adjusted EBITDA more than doubled to $37.9M.

• Total revenue grew 76.4% year-over-year to $98.7M.
• Net income increased to $27.6M, up 91.7% from Q2 2024.

D-Wave posted strong year-over-year revenue growth in Q2 2025 and ended the quarter with a record $819 million in cash, driven by successful financing activities. However, the company reported a steep net loss due to non-cash warrant remeasurement charges.

• Revenue rose to $3.1 million, up from $2.2 million a year ago
• Net loss widened significantly to $167.3 million due to non-operating charges

Americold Realty Trust reported total revenues of $650.7 million for Q2 2025, a 1.5% decrease from the prior year. Net income was $1.6 million, or $0.01 per diluted share, a significant improvement from a net loss in Q2 2024. Despite challenging demand and lower occupancy, the company made progress on operational priorities and launched new development projects.

• Total revenues for Q2 2025 were $650.7 million, a 1.5% decrease compared to Q2 2024.
• Net income for Q2 2025 was $1.6 million ($0.01 per diluted share), a substantial improvement from a net loss of $64.4 million ($0.23 per diluted share) in Q2 2024.

B2Gold posted $692,206,000 in gold revenue, basic EPS of $0.12 (adjusted EPS $0.12), $329,516,000 operating income, and strong mine performance across Fekola, Masbate, and Otjikoto; consolidated cash operating costs were $762/oz sold and AISC $1,519/oz, with cash & equivalents of $308,491,000 at quarter-end.

• Gold revenue reached $692,206,000 with 210,384 oz sold and 229,454 oz produced.
• Basic EPS was $0.12; adjusted basic EPS was also $0.12.

Installed Building Products achieved record second quarter results, with net revenue increasing 3.1% to $760.3 million and net income rising 5.8% to $69.0 million. Adjusted EBITDA also saw a 3.2% increase to $134.0 million, demonstrating strong financial performance driven by high-value installation services and strategic acquisitions.

• Net revenue reached a second quarter record of $760.3 million, marking a 3.1% increase year-over-year.
• Net income grew by 5.8% to $69.0 million, and diluted EPS increased by 9.6% to $2.52.

ESCO Technologies delivered a strong third quarter in fiscal 2025, with sales increasing 27% to $296.3 million and Adjusted EPS from Continuing Operations rising 25% to $1.60. The company saw a remarkable 194% increase in orders, reaching $749 million, leading to a record backlog of $1.17 billion. This performance was largely attributed to the strategic acquisition of Maritime and the divestiture of VACCO, which reshaped the company's portfolio towards a larger Navy business.

• Q3 2025 Sales increased 27% to $296.3 million compared to $233.6 million in Q3 2024.
• Q3 2025 Adjusted EPS from Continuing Operations increased 25% to $1.60 per share compared to $1.28 per share in Q3 2024.

Onto Innovation delivered a strong second quarter in 2025, with revenue of $253.6 million, surpassing the midpoint of its guidance. The company saw expanded adoption of its Dragonfly® 3Di metrology and sub-surface defect inspection systems, particularly in AI packaging applications. While the third quarter is expected to be a low point for revenue, the company anticipates an acceleration in AI packaging spend in the fourth quarter, returning revenue to levels consistent with the first and second quarters.

• Revenue for Q2 2025 reached $253.6 million, exceeding the midpoint of the company's guidance.
• The company expanded its Dragonfly® 3Di metrology footprint, shipping tools to over 10 customers for applications like co-packaged optics and advanced 2.5D logic packaging.

ACI Worldwide delivered solid second quarter results with a 7% increase in total revenue and a 13% rise in recurring revenue compared to the prior year. Despite a decrease in Q2 adjusted EBITDA due to the timing of higher-margin license contracts, the company raised its full-year 2025 guidance for both revenue and adjusted EBITDA, reflecting strong overall performance and strategic improvements.

• Q2 2025 revenue increased by 7% year-over-year to $401 million.
• Recurring revenue grew by 13% in Q2 2025, reaching $322 million and representing 80% of total revenue.

Grindr Inc. delivered a strong second quarter in 2025, achieving $104 million in revenue, a 27% increase year-over-year. The company reported a net income of $17 million and an Adjusted EBITDA of $45 million, demonstrating solid financial performance and progress towards its 2025 outlook.

• Revenue for Q2 2025 reached $104 million, marking a 27% increase compared to the same period last year.
• Net income for the quarter was $17 million, with a net income margin of 16%.

Acushnet Holdings Corp. delivered a strong performance in the second quarter of 2025, with net sales increasing by 5.4% year over year to $720.5 million and net income attributable to Acushnet Holdings Corp. increasing by 5.9% to $75.6 million. Adjusted EBITDA also saw a significant rise of 9.2% to $143.1 million.

• Second quarter net sales increased by 5.4% year over year to $720.5 million, or 4.7% in constant currency.
• Second quarter net income attributable to Acushnet Holdings Corp. rose by 5.9% year over year to $75.6 million.

Victory Capital achieved record financial results in Q2 2025, largely due to the successful acquisition and integration of Pioneer Investments, which significantly boosted AUM and revenue. The company also saw improved long-term net flows and maintained strong investment performance, while strengthening its financial condition through debt reduction and increased share repurchase authorization.

• Successfully closed strategic partnership with Amundi and acquired Pioneer Investments, adding $114.6 billion to AUM.
• Achieved approximately $70 million of the expected $110 million in net expense synergies by the end of June.

Arcosa, Inc. reported a record second quarter in 2025, with revenues increasing by 11% to $736.9 million and Adjusted EBITDA expanding by 37% to $154.2 million. Excluding the impact of divested businesses, Adjusted EBITDA grew by 42%. The company achieved a record Adjusted EBITDA Margin of 20.9%, up 390 basis points, and saw strong performance in its key strategic growth businesses, including a 15% cash unit profitability growth in Aggregates and record backlog in Utility Structures.

• Revenues increased 11% to $736.9 million, and 18% excluding the impact of divested businesses, highlighting successful portfolio transformation.
• Adjusted EBITDA grew 37% to $154.2 million, with a record Adjusted EBITDA Margin of 20.9%, up 390 basis points.

Prestige Consumer Healthcare Inc. reported a revenue of $249.5 million for the first quarter of fiscal 2026, a decrease of 6.6% year-over-year, mainly due to limited supply of Clear Eyes. Despite this, diluted EPS increased by approximately 6% to $0.95, and non-GAAP free cash flow saw a significant increase to $78.2 million. The company also announced the acquisition of Pillar5 Pharma to secure eye care production capacity and revised its full-year fiscal 2026 revenue and EPS outlook.

• Revenue for Q1 fiscal 2026 was $249.5 million, a 6.6% decrease from the prior year, primarily due to Clear Eyes supply constraints.
• Diluted EPS for Q1 fiscal 2026 was $0.95, an increase of approximately 6% compared to the prior year's adjusted diluted EPS of $0.90.

PTC Therapeutics experienced a decline in total revenue to $178.9 million in Q2 2025 compared to the previous year, primarily due to reduced net product sales of Translarna and Emflaza. However, the company significantly narrowed its net loss to $64.8 million and reported strong cash and cash equivalents, bolstered by the recent approvals and global launch of Sephience™.

• Total revenue for Q2 2025 was $178.9 million, a decrease from $186.7 million in Q2 2024.
• Net loss for Q2 2025 significantly improved to $64.8 million, compared to a net loss of $99.2 million in Q2 2024.

Dentsply Sirona reported a decrease in net sales by 4.9% to $936 million in Q2 2025 compared to the prior year. Despite the top-line decline, the company achieved adjusted EPS of $0.52, up from $0.49, and expanded its adjusted gross margin to 55.9% and adjusted EBITDA margin to 21.1%. The company also recorded a significant non-cash impairment charge of $214 million net of tax.

• Net sales decreased by 4.9% to $936 million in Q2 2025, or 6.7% in constant currency.
• GAAP net loss per share was ($0.22), while adjusted EPS increased to $0.52.

SoundHound AI achieved a record second quarter in 2025, with revenue reaching an all-time high of $42.7 million, marking a 217% increase year-over-year. The company demonstrated growth across all key businesses, including AI for automotive, enterprise AI for customer service, and AI automation for restaurants. While GAAP net loss was ($74.7) million, the non-GAAP net loss improved to ($11.9) million. The company also raised its full-year 2025 revenue outlook.

• Record revenue of $42.7 million, up 217% year-over-year, driven by strong performance across all business units.
• Non-GAAP net loss improved to ($11.9) million, compared to ($14.9) million in the prior year, indicating better operational efficiency.

Zai Lab reported a 9% year-over-year increase in total revenues to $110.0 million for the second quarter of 2025. The company significantly improved its operating loss by 28% year-over-year to $54.9 million, and by 37% on an adjusted basis, remaining on track to achieve profitability in the fourth quarter of 2025. Key product VYVGART showed strong growth with record patient utilization.

• Total revenues increased by 9% year-over-year to $110.0 million in Q2 2025.
• Operating loss improved by 28% year-over-year to $54.9 million, and adjusted operating loss improved by 37% to $34.2 million.

Maximus delivered a strong third quarter for fiscal year 2025, with revenue increasing by 2.5% to $1.35 billion and diluted EPS rising to $1.86. Adjusted diluted EPS also saw a significant increase to $2.16. The U.S. Federal Services Segment was a primary driver of organic growth, while the U.S. Services Segment experienced a decrease due to prior year's temporary Medicaid-related activities. The company raised its full-year fiscal 2025 guidance for revenue, adjusted EBITDA margin, and adjusted diluted EPS.

• Revenue increased by 2.5% to $1.35 billion in Q3 FY25, up from $1.31 billion in the prior year period.
• Diluted earnings per share rose to $1.86, and adjusted diluted earnings per share reached $2.16, compared to $1.46 and $1.74 respectively in the prior year.

ALLETE, Inc. reported second quarter 2025 earnings of $0.55 per share on net income of $31.9 million, down from $0.57 per share and $33.0 million in the prior year. The decline was mainly driven by lower margins from industrial customers at Minnesota Power and increased operating and depreciation expenses, although these were partially offset by significantly lower merger-related expenses compared to 2024.

• Net income for Q2 2025 was $31.9 million, a decrease from $33.0 million in Q2 2024.
• Diluted EPS for Q2 2025 was $0.55, down from $0.57 in Q2 2024.

Tecnoglass achieved record quarterly revenue of $255.5 million, a 16.3% increase year-over-year, with double-digit organic growth in both single-family residential and multi-family/commercial segments. The company also reported a strong gross margin of 44.7% and adjusted EBITDA of $79.8 million, demonstrating robust profitability and operational efficiency. Backlog expanded to a record $1.2 billion, providing strong future visibility.

• Record quarterly revenue of $255.5 million, up 16.3% year-over-year, with strong organic growth across segments.
• Gross margin expanded by 400 basis points year-over-year to 44.7%, reflecting improved pricing and operational leverage.

MDU Resources Group, Inc. announced its second quarter 2025 financial results, showing a decline in net income and diluted EPS compared to the prior year. The company's performance was impacted by higher operation and maintenance expenses and warmer weather, particularly affecting the natural gas distribution segment. However, the pipeline segment demonstrated solid performance with increased transportation revenue, and the electric utility segment saw a significant increase in retail sales volumes driven by data center demand. The company narrowed its full-year earnings guidance.

• Net income for the second quarter of 2025 was $13.7 million, a significant decrease from $60.4 million in the same period last year.
• Diluted earnings per share for the quarter were $0.07, down from $0.30 in the second quarter of 2024.

CarGurus delivered a strong second quarter in its Marketplace business, with revenue increasing by 14% year-over-year. The company reported a net income of $22.3 million and a non-GAAP Adjusted EBITDA of $77.3 million, up 39% year-over-year. Concurrently, CarGurus announced its strategic decision to wind down the CarOffer transactions business to focus on technology and analytics for smarter sourcing decisions.

• Marketplace revenue grew by 14% year-over-year, demonstrating sustained strong performance in this core segment.
• The company achieved a net income of $22.3 million and a significant 39% year-over-year increase in Non-GAAP Adjusted EBITDA to $77.3 million.

ICU Medical reported second quarter 2025 revenue of $548.9 million, a decrease from $596.5 million in the prior year. Despite the revenue decline, the company achieved a GAAP net income of $35.3 million, a substantial improvement from a net loss in Q2 2024. Adjusted diluted EPS also saw a notable increase to $2.10.

• Second quarter 2025 revenue was $548.9 million, a decrease from $596.5 million in the same period last year.
• GAAP net income for Q2 2025 was $35.3 million, a significant turnaround from a GAAP net loss of $(21.4) million in Q2 2024.

Globalstar delivered strong second quarter 2025 results with revenue increasing 11% to $67.1 million and net income reaching $19.2 million. Adjusted EBITDA for the quarter was $35.8 million, reflecting a 53% margin. The company is on track with its infrastructure expansion plan for the C-3 satellite system and has reaffirmed its full-year financial guidance.

• Total revenue for Q2 2025 increased by 11% year-over-year to $67.1 million, primarily due to growth in wholesale capacity services and Commercial IoT.
• Net income for the second quarter was $19.2 million, a significant improvement from a net loss in the prior year period.

First Advantage delivered solid financial performance in the second quarter of 2025, meeting the high end of its expectations despite macroeconomic uncertainties. The company reported revenues of $390.6 million and adjusted diluted earnings per share of $0.27, driven by a balanced vertical strategy and consistent market execution. Strategic priorities, including the integration of Sterling Check Corp. and advancements in product and technology, contributed to the results, alongside momentum in international markets and strong interest in Digital Identity solutions.

• Revenues for Q2 2025 reached $390.6 million, demonstrating solid top-line performance.
• Adjusted Diluted Earnings Per Share was $0.27, indicating strong non-GAAP profitability.

Alarm.com delivered a strong second quarter in 2025, with significant growth across key financial metrics. SaaS and license revenue, total revenue, GAAP net income, and non-GAAP adjusted EBITDA all saw healthy increases year-over-year, demonstrating robust performance in its core business and overall financial health.

• SaaS and license revenue increased by 9.0% to $170.0 million, up from $155.9 million in Q2 2024.
• Total revenue grew by 8.8% to $254.3 million, compared to $233.8 million in the prior year's second quarter.

Aspen Insurance Holdings Limited delivered a strong performance in the second quarter of 2025, with net income available to ordinary shareholders reaching $35.5 million and operating income at $110.9 million. The company achieved an improved combined ratio of 85.1% and an annualized operating return on average equity of 17.2%. Growth in the Insurance segment was partially offset by selective reductions in the Reinsurance segment due to market conditions.

• Net income available to ordinary shareholders for Q2 2025 was $35.5 million, or $0.39 per diluted ordinary share.
• Operating income for Q2 2025 was $110.9 million, or $1.22 per diluted ordinary share.

TEGNA delivered on its financial commitments in Q2 2025, with total revenue decreasing 5% to $675 million, in line with guidance. This decline was mainly driven by lower political advertising revenue and advertising and marketing services (AMS) revenue. Despite the revenue decrease, the company saw flat distribution revenue and managed to reduce GAAP operating expenses by 3% to $553 million, leading to a GAAP net income of $68 million and non-GAAP EPS of $0.44.

• Total company revenue decreased 5% to $675 million, aligning with guidance, primarily due to lower political advertising and AMS revenue.
• Distribution revenue remained flat at $370 million, with contractual rate increases offsetting subscriber declines.

Privia Health delivered a very strong performance in the second quarter of 2025, exceeding expectations with substantial growth in revenue, practice collections, and profitability. The company's strategic initiatives, including new provider additions and expansion into new markets, contributed to robust financial outcomes and led to raised full-year guidance.

• Total revenue increased by 23.4% to $521.2 million in Q2 2025, up from $422.3 million in Q2 2024.
• Adjusted EBITDA grew by 31.6% to $29.0 million, demonstrating strong profitability improvements.

Concentra Group Holdings delivered robust performance in the second quarter of 2025, with revenue increasing by 15.2% to $550.8 million and Adjusted EBITDA growing by 13.2% to $115.0 million. The company saw a 9.5% increase in patient visits per day and a 4.4% rise in revenue per visit. Net income was $46.2 million, and Adjusted EPS was $0.37. The company also successfully integrated recent acquisitions, expanding its network to over 1,000 locations.

• Revenue increased by 15.2% to $550.8 million in Q2 2025, up from $477.9 million in Q2 2024.
• Adjusted EBITDA grew by 13.2% to $115.0 million, compared to $101.6 million in the prior year's quarter.

Warby Parker reported a strong second quarter in 2025, with net revenue increasing by 13.9% year-over-year to $214.5 million. The company significantly improved its net loss to $1.8 million and saw a rise in active customers and average revenue per customer. Adjusted EBITDA also increased, demonstrating improved operational efficiency.

• Net revenue for Q2 2025 increased by 13.9% to $214.5 million compared to the prior year period.
• Active Customers grew by 9.0% to 2.60 million on a trailing 12-month basis, and Average Revenue per Customer increased by 4.6% to $316.

CleanSpark delivered its most successful quarter to date in Q3 fiscal 2025, with record revenues of $198.6 million and basic EPS of $0.90. The company significantly expanded its operational hashrate to 50 EH/s and grew its Bitcoin treasury to over $1 billion, all while funding operations through Bitcoin production.

• Achieved record quarterly revenue of $198.6 million, marking a 91% increase year-over-year.
• Reported a net income of $257.4 million and a record basic EPS of $0.90.

RXO's second quarter performance was marked by a significant increase in revenue to $1.4 billion, up from $930 million in the prior year. The company achieved a positive adjusted net income of $7 million and an adjusted EBITDA of $38 million, demonstrating resilience in a challenging freight market. Brokerage volume grew by 1% year-over-year, primarily due to a substantial increase in less-than-truckload volume, while Last Mile continued its double-digit stop growth.

• Revenue for Q2 2025 reached $1.4 billion, a substantial increase from $930 million in Q2 2024.
• Adjusted EBITDA improved to $38 million, up from $28 million in the same period last year.

Peloton delivered $606.9M in revenue and $21.6M in net income during Q4 2025, achieving positive free cash flow and its first quarterly profit in over two years.

• Returned to profitability with $21.6M in net income.
• Generated $112.4M in free cash flow during the quarter.

Synaptics reported a revenue of $282.8 million for Q4 FY2025, with a GAAP net loss of $4.7 million and non-GAAP net income of $39.5 million. Core IoT product sales grew by 55% year-over-year in Q4. For the full fiscal year 2025, revenue increased by 12% to $1.074 billion, primarily fueled by a 53% growth in Core IoT product sales. The company also announced a new share repurchase program of up to $150 million.

• Q4 FY2025 revenue reached $282.8 million.
• Core IoT product sales in Q4 FY2025 increased by 55% compared to the previous year.

YETI's second quarter of 2025 saw a 4% decrease in net sales to $445.9 million, primarily due to a promotional drinkware market, consumer caution, and supply chain constraints. Despite this, GAAP EPS increased by 3% to $0.61 and net income rose by 1% to $51.2 million. Adjusted EPS, however, decreased by 6% to $0.66, impacted by higher tariff costs. The company is making progress on strategic priorities including innovation, global brand expansion, and supply chain diversification, and raised its full-year EPS outlook.

• Net sales decreased by 4% to $445.9 million, attributed to a promotional drinkware market, cautious consumers, and supply chain issues.
• GAAP EPS increased by 3% to $0.61, and net income rose by 1% to $51.2 million.

United Parks & Resorts Inc. experienced a challenging second quarter in 2025, with total revenue decreasing by 1.5% to $490.2 million and net income falling by 12.1% to $80.1 million. Despite these declines, attendance saw a modest increase of 0.8% to 6.2 million guests, primarily due to a favorable calendar shift of holidays, though this was partially offset by adverse weather conditions.

• Total revenue for Q2 2025 was $490.2 million, a 1.5% decrease from Q2 2024.
• Net income for Q2 2025 was $80.1 million, a 12.1% decrease from Q2 2024.

Trupanion, Inc. announced a strong second quarter for 2025, with total revenue increasing by 12% to $353.6 million and net income reaching $9.4 million, a significant improvement from a net loss in the prior year. The company also saw robust growth in subscription business revenue and adjusted EBITDA.

• Total revenue increased by 12% to $353.6 million compared to Q2 2024.
• Net income was $9.4 million, or $0.22 per basic and diluted share, a substantial improvement from a net loss of $(5.9) million in Q2 2024.

Diodes Incorporated delivered strong second-quarter fiscal 2025 results, with revenue reaching $366.2 million, a 14% increase year-over-year. The company reported GAAP net income of $46.1 million and GAAP EPS of $0.99 per diluted share, significantly up from the prior year. Non-GAAP EPS was $0.32. Gross profit stood at $115.3 million, with a gross profit margin of 31.5%. The company also generated $41.5 million in cash flow from operations and $21.1 million in free cash flow.

• Revenue for Q2 2025 was $366.2 million, marking a 10% sequential increase and 14% year-over-year growth, exceeding expectations.
• GAAP net income significantly improved to $46.1 million, compared to $8.0 million in Q2 2024, and GAAP EPS rose to $0.99 per diluted share from $0.17.

Walker & Dunlop delivered a strong performance in the second quarter of 2025, with total transaction volume increasing by 65% to $14.0 billion and total revenues growing by 18% to $319.2 million. Net income saw a substantial 50% increase to $34.0 million, and diluted EPS rose by 48% to $0.99. The company's servicing portfolio also expanded by 3% to $137.3 billion.

• Total transaction volume surged by 65% year-over-year, reaching $14.0 billion, indicating strong market demand.
• Total revenues increased by 18% to $319.2 million, reflecting broad-based strength across transaction types.

Yelp delivered a strong second quarter in 2025, achieving record net revenue of $370 million, a 4% increase year-over-year. Net income grew by 16% to $44 million, with an expanded net income margin of 12%. Adjusted EBITDA also saw significant growth, rising 10% to $100 million, reflecting a 27% margin. The company highlighted encouraging momentum from its AI initiatives, including Yelp Assistant and Yelp Host, and maintained a disciplined financial approach despite a moderating macroeconomic environment.

• Net Revenue reached a record $370 million, marking a 4% year-over-year increase.
• Net Income increased by 16% year-over-year to $44 million, with a 12% net income margin.

Ligand Pharmaceuticals reported a robust second quarter in 2025, with total revenues increasing by 15% year-over-year, primarily due to a 57% surge in royalty revenue. The company also significantly raised its full-year 2025 revenue and adjusted EPS guidance, reflecting continued strength in its commercial-stage royalty portfolio and key partnership milestones.

• Total revenues for Q2 2025 reached $47.6 million, a 15% increase from Q2 2024.
• Royalty revenue grew by 57% to $36.4 million in Q2 2025, driven by Qarziba and Filspari.

Arrowhead Pharmaceuticals reported a net loss of $175.241 million for the fiscal third quarter of 2025, with revenue of $27.767 million. The company maintained a strong balance sheet with total cash resources of $900.372 million and advanced several key pipeline candidates, including plozasiran, zodasiran, and ARO-ALK7, into late-stage or early-stage clinical trials.

• Arrowhead Pharmaceuticals reported revenue of $27.767 million for the fiscal third quarter of 2025.
• The company posted a net loss of $175.241 million, or $1.26 per diluted share, for the quarter.

VIAVI concluded Fiscal 2025 with robust fourth-quarter performance, meeting the upper range of its guidance. The company experienced stabilization in its core service provider test and measurement, and optical security pigments businesses, while growth in data center ecosystem and aerospace & defense segments further accelerated its recovery. Management anticipates continued positive momentum in its end markets through calendar year 2025.

• VIAVI's Q4 2025 net revenue reached $290.5 million, marking a 15.3% increase year-over-year.
• GAAP diluted EPS for Q4 2025 was $0.04, a significant improvement from a loss of $0.10 in the prior year.

Appian delivered robust financial performance in Q2 2025, with total revenue increasing 17% year-over-year to $170.6 million. The company significantly reduced its GAAP operating loss and net loss, achieving non-GAAP operating income and net income, and a positive Adjusted EBITDA, indicating improved operational efficiency and profitability.

• Total revenue for Q2 2025 reached $170.6 million, marking a 17% increase year-over-year.
• Cloud subscriptions revenue grew by 21% year-over-year to $106.9 million, demonstrating strong growth in this key segment.

Lionsgate Studios reported a challenging first quarter for fiscal 2026, with a significant net loss and operating loss. Despite a decrease in overall studio revenue compared to the prior year, the Television Production segment showed strong growth. The company highlighted a record trailing 12-month library revenue, indicating continued strength in its content library.

• Studio revenue for the first quarter was $555.9 million, a decrease from $590.7 million in the prior year.
• The company reported an operating loss of $10.6 million and a net loss from continuing operations attributable to shareholders of $94.0 million.

LifeStance Health Group delivered a robust performance in the second quarter of 2025, with revenue increasing by 11% to $345.3 million. The company significantly reduced its net loss from $23.3 million in Q2 2024 to $3.8 million in Q2 2025, and saw a 19% increase in Adjusted EBITDA to $34.0 million. The clinician base expanded by 11% to 7,708, contributing to a 12% rise in visit volumes.

• Revenue increased by 11% year-over-year to $345.3 million, driven by higher visit volumes and clinician growth.
• Net loss significantly improved by 84% to $3.8 million, compared to a net loss of $23.3 million in the prior-year period.

Gogo reported a robust second quarter in 2025, with total revenue increasing by 121% year-over-year to $226.0 million, primarily boosted by the Satcom Direct acquisition. Net income saw a substantial rise to $12.8 million, and the company generated strong free cash flow, leading to an increase in its full-year financial guidance.

• Total revenue reached $226.0 million, marking a 121% increase year-over-year, with Satcom Direct contributing $122.8 million.
• Net income significantly improved to $12.8 million, up from $0.8 million in Q2 2024.

Hut 8 Corp delivered $41.3M in revenue and $137.5M in net income driven by robust compute segment performance, favorable digital asset gains, and expanded long-term energy contracts.

• Revenue increased to $41.3M driven by a 117% year-over-year growth in Compute segment.
• Net income of $137.5M included $217.6M in gains on digital assets.

Global Partners experienced a decline in profitability in the second quarter of 2025, with net income falling to $25.2 million from $46.1 million in Q2 2024, and adjusted EBITDA decreasing to $98.2 million from $121.1 million. However, the company saw an increase in total sales to $4.6 billion and total volume to 2.0 billion gallons, driven primarily by growth in the wholesale segment.

• Net income for Q2 2025 was $25.2 million, a significant decrease from $46.1 million in Q2 2024.
• Adjusted EBITDA for the quarter was $98.2 million, down from $121.1 million in the prior year.

Progyny, Inc. announced strong financial results for the second quarter of 2025, with record revenue of $332.9 million, a 9.5% increase year-over-year. The company also reported significant growth in gross profit and net income, alongside robust operating cash flow. This performance was primarily attributed to increased member engagement and an expanded client base.

• Record revenue of $332.9 million, marking a 9.5% increase from Q2 2024.
• Gross profit rose by 16% to $79.0 million, with gross margin expanding to 23.7%.

Disc Medicine reported a net loss of $55.2 million for Q2 2025, an increase from $26.4 million in Q2 2024, primarily due to higher operating costs driven by the progression of its clinical pipeline. The company ended the quarter with a strong cash position of $650.0 million, expected to fund operations into 2028.

• Disc Medicine is on track to submit an NDA for bitopertin in erythropoietic protoporphyria (EPP) under the accelerated approval pathway in October 2025.
• The company expects initial data from the Phase 2 study of DISC-0974 in anemia of myelofibrosis (MF) and multiple dose data from the Phase 1b study of DISC-0974 in anemia of non-dialysis-dependent chronic kidney disease (NDD-CKD) in Q4 2025.

Arlo Technologies achieved record financial results in Q2 2025, primarily fueled by the success of its new AI platform, Arlo Secure 6, which significantly boosted subscriptions and services revenue and annual recurring revenue. The company also reported record gross margins and adjusted EBITDA.

• Annual Recurring Revenue (ARR) reached $316 million, marking a 34% year-over-year increase.
• Subscriptions and services revenue hit a record $78 million, growing 30% compared to the previous year.

Enovis reported strong second-quarter 2025 results with net sales of $565 million, a 7% increase year-over-year. The company experienced continued execution in its Prevention & Recovery and Reconstructive segments, stable end markets, and positive momentum from new product introductions. Despite a GAAP net loss of $37 million, adjusted EBITDA reached $97 million, reflecting solid operational performance. The company also updated its full-year 2025 financial outlook, raising revenue and adjusted EBITDA guidance.

• Second-quarter net sales increased by 7% on a reported basis and 5% organically compared to the same period in 2024, reaching $565 million.
• The Reconstructive segment demonstrated significant growth, with sales increasing 11% on a reported basis and 8% organically year-over-year.

NETSCOUT delivered a solid start to fiscal year 2026, with Q1 performance reflecting strong execution and positive momentum across both top- and bottom-lines. The company saw increased total revenue, product revenue, and significant improvements in GAAP and non-GAAP operating income and net income compared to the prior year, largely due to the absence of the large goodwill impairment charge from the previous year. Growth in Cybersecurity and Service Assurance product lines supported these results.

• Total revenue increased to $186.7 million in Q1 FY26, up from $174.6 million in Q1 FY25.
• GAAP loss from operations significantly improved to $6.6 million from $463.3 million in the prior year, primarily due to the absence of a goodwill impairment charge.

Papa John's delivered a strong second quarter, with total revenues increasing by 4% to $529.2 million, driven primarily by higher Commissary revenues. The company returned to comparable sales growth in North America and achieved robust international sales growth, contributing to a 4% increase in global system-wide restaurant sales. Despite higher revenues, net income decreased to $9.7 million due to increased G&A expenses and higher cost of sales.

• Total revenues increased by 4% to $529.2 million, primarily due to a $20.3 million increase in Commissary revenues.
• North America comparable sales increased by 0.9%, with Domestic Company-owned restaurants flat and North America franchised restaurants up 1%.

NCR Voyix experienced a decline in total revenue for Q2 2025, reaching $666 million, down from $722 million in the prior year. However, the company significantly improved its profitability, reporting a net income of $1 million compared to a net loss of $90 million in Q2 2024, and an increase in Adjusted EBITDA to $95 million from $79 million.

• Total revenue for Q2 2025 was $666 million, an 8% decrease from $722 million in Q2 2024.
• Net income from continuing operations attributable to NCR Voyix was $1 million, a significant improvement from a net loss of $90 million in the prior year period.

Immunocore announced robust second quarter 2025 financial results, with KIMMTRAK net product sales reaching $98.0 million, a 30% year-over-year increase. The company reported a net loss of $10.3 million and a loss per share of $0.20, showing an improvement compared to the same period last year. Significant progress was made in advancing its Phase 3 trials for TEBE-AM and PRISM-MEL-301, alongside the expansion of KIMMTRAK's global reach.

• KIMMTRAK net product sales reached $98.0 million in Q2 2025, marking a 30% year-over-year increase.
• The company's net loss improved to $10.3 million in Q2 2025, down from $11.6 million in Q2 2024.

Hanesbrands Inc. delivered strong second-quarter 2025 results, exceeding expectations with a 1.8% increase in net sales to $991 million. The company saw significant improvements in profitability, with gross margin rising to 41.6% and operating profit surging by 345% to $155 million. Diluted EPS increased by 162% to $0.24. The balance sheet was strengthened with a reduced leverage ratio of 3.3 times.

• Net Sales increased by 1.8% year-over-year, reaching $991 million, exceeding expectations for the third consecutive quarter.
• Gross Margin significantly improved by 1,100 basis points to 41.6%, driven by cost savings, productivity initiatives, and lower input costs.

LegalZoom delivered a strong second quarter in 2025, with revenue reaching $192.5 million, a 9% increase year-over-year. The company achieved double-digit subscription growth ahead of schedule and maintained strong profitability, reporting an Adjusted EBITDA of $39.0 million. Despite a net loss of $0.3 million, the company demonstrated solid execution against its strategic priorities and raised its full-year revenue growth outlook.

• Second quarter revenue of $192.5 million exceeded the high end of the outlook range, growing 9% year-over-year.
• Subscription revenue increased by 10% year-over-year to $119.9 million, achieving double-digit growth two quarters ahead of plan.

Edgewise Therapeutics reported a net loss of $36.1 million for the second quarter of 2025, an improvement from the previous quarter's $40.8 million loss. The company's cash, cash equivalents, and marketable securities stood at approximately $594.0 million, indicating a strong financial position to advance its clinical programs.

• Net loss for Q2 2025 was $36.1 million, an improvement from the previous quarter.
• Cash, cash equivalents, and marketable securities were approximately $594.0 million as of June 30, 2025.

Rapid7 delivered a solid second quarter in 2025, with total revenue increasing by 3% year-over-year to $214.193 million and annualized recurring revenue (ARR) reaching $840.610 million, also up 3%. The company saw a significant increase in free cash flow to $42.280 million and reported GAAP net income of $8.338 million, demonstrating improved profitability.

• Total revenue grew 3% year-over-year to $214.193 million, driven primarily by product subscriptions.
• Annualized Recurring Revenue (ARR) increased by 3% year-over-year, reaching $840.610 million.

ProFrac Holding Corp. experienced a challenging second quarter of 2025, with total revenue decreasing to $502 million from $600 million in the previous quarter, and a net loss of $104 million, significantly wider than the $15 million net loss in Q1 2025. Despite market headwinds, the company emphasized its operational excellence, particularly in asset management, which contributed to positive free cash flow of $54 million.

• Total revenue for Q2 2025 was $502 million, a decrease from $600 million in Q1 2025.
• The company reported a net loss of $104 million in Q2 2025, compared to a net loss of $15 million in the prior quarter.

TaskUs delivered a strong second quarter in 2025, with total revenues reaching $294.1 million, marking a 23.6% year-over-year increase. The company also reported a net income of $20.0 million and an Adjusted Net Income of $39.7 million, demonstrating robust profitability. Diluted EPS was $0.22, with Adjusted EPS at $0.43.

• Total revenues for Q2 2025 were $294.1 million, representing a 23.6% year-over-year growth.
• Net income for the quarter was $20.0 million, with an Adjusted Net Income of $39.7 million.

Sweetgreen experienced a challenging second quarter in fiscal year 2025, with total revenue increasing marginally by 0.5% to $185.6 million. The company reported a net loss of $23.2 million, a significant increase from the $14.5 million loss in the prior year, primarily due to a decrease in Restaurant-Level Profit and increased impairment and closure costs. Despite headwinds, the company is confident in improving performance in the latter half of 2025, driven by a new loyalty program and summer menu.

• Total revenue for Q2 2025 was $185.6 million, a modest 0.5% increase year-over-year, primarily driven by new restaurant openings.
• Net loss widened to $23.2 million in Q2 2025, compared to a $14.5 million net loss in Q2 2024, mainly due to reduced Restaurant-Level Profit and higher impairment costs.

CompoSecure delivered a strong second quarter in 2025, achieving record financial results driven by accelerating sales and improved profitability. The company saw robust domestic demand from both traditional banks and fintechs, alongside a net positive quarter for Arculus. Significant gross margin improvement was noted, attributed to the CompoSecure Operating System (COS), which is enhancing execution and profitability. The company also raised its full-year 2025 guidance.

• Non-GAAP Net Sales increased by 10% year-over-year to $119.6 million, driven by strong domestic demand from traditional financial institutions and fintech partners.
• Non-GAAP Gross Profit rose to $68.8 million, with gross margin expanding to 57.5%, reflecting improved manufacturing efficiencies and favorable product mix.

N-able delivered a strong second quarter, with total revenue reaching $131.2 million, a 9.9% year-over-year increase. The company also achieved a significant milestone by surpassing $500 million in total ARR, demonstrating robust growth in its subscription-based services and strong execution against its financial guidance.

• Total revenue for Q2 2025 was $131.2 million, marking a 9.9% year-over-year growth.
• Subscription revenue grew by 10.6% year-over-year to $129.9 million.

Pagaya Technologies Ltd. delivered a strong second quarter in 2025, marked by record performance across key financial metrics. The company achieved positive GAAP net income for the second consecutive quarter, significantly increasing net income attributable to shareholders by $91 million year-over-year. Total revenue and other income grew by 30% year-over-year, and adjusted EBITDA saw a substantial 72% increase. Network volume also reached a record high, growing by 14% year-over-year, driven by strong performance in Auto and Point-of-Sale verticals. The company successfully issued its first AAA-rated Auto ABS and inaugural AAA-rated Point-of-Sale revolving ABS structures, alongside a successful $500 million Senior Unsecured Notes issuance.

• Net income attributable to Pagaya shareholders reached $17 million, marking a significant increase of $91 million year-over-year.
• Total revenue and other income grew by 30% year-over-year, reaching a record $326 million.

10x Genomics reported a revenue of $172.9 million for Q2 2025, which includes a significant patent litigation settlement. Excluding this settlement, revenue decreased by 5% year-over-year, primarily due to lower instrument sales. Despite a challenging funding environment, the company achieved net income and improved its gross margin and operating income compared to the prior year.

• Revenue for Q2 2025 was $172.9 million, including $27.3 million from a patent litigation settlement.
• Excluding the settlement, revenue was $145.6 million, a 5% decrease year-over-year, mainly due to decreased instrument revenue.

Applied Optoelectronics reported strong year-over-year revenue growth and gross margin expansion in Q2 2025, driven by strength in both datacenter and CATV businesses. Despite a net loss, the company made strategic investments in R&D and SG&A, particularly for 800G and 1.6Tb transceivers, which are expected to translate into future revenue opportunities.

• Revenue for Q2 2025 was $103.0 million, a significant increase from $43.3 million in Q2 2024.
• GAAP gross margin improved to 30.3% in Q2 2025, up from 22.1% in the same period last year.

Integral Ad Science (IAS) delivered a robust performance in the second quarter of 2025, with total revenue increasing by 16% to $149.2 million. The company saw gains across all business segments, driven by strong adoption of its AI-powered products. Net income rose to $16.4 million, achieving an 11% margin, while adjusted EBITDA increased to $51.6 million with a 35% margin. These positive results led IAS to raise its full-year 2025 financial outlook.

• Total revenue grew 16% year-over-year to $149.2 million, demonstrating strong overall business expansion.
• Net income significantly increased to $16.4 million, resulting in an 11% net income margin for the quarter.

Spectrum Brands faced a challenging quarter with significant sales declines across all segments due to strategic decisions related to tariffs, supply chain disruptions, and soft consumer demand. Despite these headwinds, the company saw an increase in net income from continuing operations and reaffirmed its free cash flow guidance for fiscal 2025, indicating a focus on long-term stability and cost reduction.

• Net sales decreased by 10.2% to $699.6 million, with organic net sales declining by 11.1%, primarily due to stop shipments during tariff-related pricing negotiations and supply constraints.
• Net income from continuing operations increased by 7.3% to $20.5 million, driven by lower interest costs, lower taxes, and a reduced share count.

Artivion delivered an exceptionally strong second quarter in 2025, achieving $113.0 million in revenue, a 15% increase year-over-year. The company reported a net income of $1.3 million and a non-GAAP net income of $10.7 million. Adjusted EBITDA saw a substantial 33% increase to $24.8 million, demonstrating the company's ability to scale and expand margins. Key drivers for revenue growth included On-X and stent grafts, both growing over 20% on a constant currency basis.

• Total revenue for Q2 2025 reached $113.0 million, marking a 15% increase from Q2 2024.
• Net income for the quarter was $1.3 million, with non-GAAP net income at $10.7 million.

Cipher Mining reported a net loss of $46 million in the second quarter of 2025, or $0.12 per share, but achieved non-GAAP adjusted earnings of $30 million, or $0.08 per diluted share. The company successfully commenced hashing at Black Pearl Phase I ahead of schedule, increasing its total self-mining capacity to approximately 16.8 EH/s, and is on track to reach 23.5 EH/s by the end of Q3 2025. The company is also strategically developing Black Pearl Phase II to support both AI compute and hydro-bitcoin mining.

• Cipher Mining reported a net loss of $45.781 million for Q2 2025, compared to a net loss of $15.291 million in Q2 2024.
• Non-GAAP Adjusted Earnings were $30.349 million, or $0.08 per diluted share, a significant improvement from a loss of $3.490 million in Q2 2024.

Ellington Financial delivered a strong second quarter, generating net income of $0.45 per share and an annualized economic return of 13.8%. Book value per share increased to $13.49, and adjusted distributable earnings per share rose sharply to $0.47, significantly exceeding dividends paid.

• Net income attributable to common stockholders was $42.9 million, or $0.45 per common share.
• Adjusted Distributable Earnings reached $45.0 million, or $0.47 per common share, surpassing dividends of $0.39 per share.

Dynavax delivered robust Q2 2025 results, achieving record quarterly net product revenue for HEPLISAV-B of $91.9 million, a 31% increase year-over-year. The company reported a GAAP net income of $18.7 million and an EPS of $0.14 diluted. HEPLISAV-B's U.S. market share increased to approximately 45%.

• Record HEPLISAV-B quarterly net product revenue of $91.9 million, up 31% year-over-year.
• HEPLISAV-B's U.S. market share increased to approximately 45% in Q2 2025.

Arhaus achieved its highest quarterly net revenue in history, exceeding $358 million, driven by strong brand performance and efficient operations. The company saw significant increases in net income and adjusted EBITDA, reflecting effective conversion of demand despite macroeconomic headwinds. Arhaus also expanded its product offerings and continued its showroom project initiatives, maintaining a strong financial position with no long-term debt.

• Net revenue increased 15.7% to a record $358 million, marking the highest quarterly net revenue in Arhaus' history.
• Net and comprehensive income surged by 57.7% to $35 million, demonstrating strong profitability.

Ducommun delivered an excellent second quarter, with net revenue growing 3% year-over-year to $202.3 million, driven by robust demand in the defense business. The company achieved record gross margin of 26.6% and Adjusted EBITDA margin of 16.0%, leading to a 63% increase in net income to $12.6 million.

• Net revenue increased by 3% year-over-year to $202.3 million, primarily due to strong performance in military and space end-use markets.
• Gross margin reached a record 26.6%, expanding 60 basis points year-over-year, reflecting improved manufacturing efficiency and lower restructuring charges.

Jamf announced strong second quarter 2025 financial results, with total revenue increasing 15% year-over-year to $176.5 million and adjusted EBITDA growing 40% year-over-year to $35.3 million. The company exceeded its outlook for both revenue and profitability, attributing success to a strategic reinvestment plan focused on growth opportunities, AI capabilities, and platform strategy alignment.

• Total revenue for Q2 2025 increased by 15% year-over-year to $176.5 million.
• Adjusted EBITDA for Q2 2025 grew by 40% year-over-year to $35.3 million, representing 20% of total revenue.

Astrana Health delivered total revenue of 654800000 in Q2 2025, up approximately 35% year-over-year, with net income of 9400000 and adjusted EBITDA of 48100000. EPS was reported at 0.19 per share as the company continued to expand its value-based care operations and integrate the Prospect Health acquisition.

• Total revenue grew 35% year-over-year to 654800000.
• Adjusted EBITDA for the quarter was 48100000, at the high end of guidance.

Marcus & Millichap demonstrated resilience in Q2 2025 with an 8.8% increase in total revenue, reaching $172.3 million, driven by strong performance in its financing business and Private Client Market segment. Despite a net loss of $11.0 million, largely due to a tax methodology change, the company saw growth in transaction activity and maintained comparable Adjusted EBITDA.

• Total revenue increased by 8.8% to $172.3 million in Q2 2025, up from $158.4 million in Q2 2024.
• Net loss for Q2 2025 was $11.0 million, or $0.28 per diluted common share, compared to a net loss of $5.5 million, or $0.14 per diluted common share, in Q2 2024.

Ouster reported a strong second quarter in 2025, with revenue reaching $35 million, a 30% increase year-over-year. The company achieved a GAAP gross margin of 45% and a non-GAAP gross margin of 52%, demonstrating significant improvements. Net loss improved to $21 million, and adjusted EBITDA loss narrowed to $6 million, indicating progress towards profitability. The company also shipped a record 5,500 sensors, driven by demand in industrial and automotive verticals.

• Revenue reached $35 million, marking a 30% year-over-year increase and the tenth consecutive quarter of revenue growth.
• GAAP gross margin improved significantly to 45%, up 1100 basis points year-over-year, while non-GAAP gross margin rose to 52%.

Array Technologies delivered a robust second quarter in 2025, with significant sequential revenue growth and improved margins. The company's strategic initiatives, including the acquisition of APA Solar and the launch of Hail XP™, along with a strengthened capital structure, position it for continued long-term growth in the utility-scale solar market.

• Revenue for Q2 2025 reached $362.2 million, demonstrating 20% sequential growth.
• Gross margin improved to 26.8%, with adjusted gross margin at 27.8%.

RLJ Lodging Trust delivered strong second quarter results, surpassing expectations due to portfolio resiliency, continued ramp-up of conversions, and effective cost controls. The company reported total revenues of $363.1 million, net income of $28.6 million, and adjusted FFO per diluted common share and unit of $0.48. Strategic initiatives included advancing renovations, addressing near-term maturities, and executing accretive share repurchases.

• Total Revenues reached $363.1 million, a slight decrease of 1.7% year-over-year.
• Net Income was $28.6 million, with Net Income per share attributable to common shareholders at $0.15.

Establishment Labs reported a strong second quarter in 2025, with worldwide revenue increasing by 16.3% year-over-year to $51.3 million, driven by significant Motiva sales in the United States. The company also improved its gross margin to 68.8% and reduced its adjusted EBITDA loss and cash use compared to the previous quarter, indicating increasing scale and improved cost efficiencies. The company raised its full-year revenue guidance.

• Worldwide revenue for Q2 2025 reached $51.3 million, a 16.3% increase year-over-year.
• Gross margin improved to 68.8% in Q2 2025, up from 65.6% in the prior year period.

VTEX delivered a strong second quarter in 2025, with total revenue reaching US$58.8 million and non-GAAP income from operations at US$8.5 million, exceeding expectations and leading to raised full-year guidance for non-GAAP income from operations and free cash flow margins. The company saw significant growth in subscription revenue and non-GAAP subscription gross profit, alongside strategic customer acquisitions and expansions in key global markets.

• Total revenue increased to US$58.8 million, a 4.0% YoY increase in USD and 9.0% on an FX neutral basis.
• Non-GAAP income from operations reached US$8.5 million, representing a 14.4% margin and a 3.3 percentage point margin increase year-over-year.

Fox Factory Holding Corp. delivered significant progress in the second quarter of fiscal 2025 with net sales of $374.9 million, an increase of 7.6% year-over-year. The growth was observed across all three segments, both sequentially and year-over-year, accompanied by continued improvement in adjusted EBITDA margin. Despite challenges like shifts in product mix and tariffs impacting gross margin, the company's operational improvements and strategic cost management initiatives yielded positive results on the bottom line.

• Net sales for Q2 2025 reached $374.9 million, a 7.6% increase compared to Q2 2024.
• All three segments (Specialty Sports Group, Aftermarket Applications Group, and Powered Vehicles Group) showed sequential and year-over-year growth.

Hertz Global Holdings, Inc. achieved its best quarterly results in nearly two years, with net income and Adjusted Corporate EBITDA improving by approximately $0.5 billion year-over-year. The company reported its first quarter of positive Adjusted Corporate EBITDA in almost two years, demonstrating the effectiveness of its 'Buy Right, Hold Right, Sell Right' strategy, improved vehicle utilization, and disciplined cost control.

• Net income and Adjusted Corporate EBITDA improved by approximately $0.5 billion year-over-year, marking the first quarter of positive Adjusted Corporate EBITDA in nearly two years.
• Depreciation per unit per month (DPU) reached $251, exceeding the North Star target of sub $300 by 16%, with all Model Year 2025 fleet secured at pre-tariff pricing.

SolarEdge reported a revenue of $289.41 million for Q2 2025, a 32% increase from the prior quarter. The company experienced a GAAP net loss of $124.74 million and a non-GAAP net loss of $47.67 million. Despite the losses, the company showed sequential improvements in revenue, gross margin, and operating loss, indicating progress in its turnaround efforts.

• Revenue for Q2 2025 was $289.41 million, marking a 32% increase from the prior quarter.
• GAAP gross margin improved to 11.1% from 8.0% in the prior quarter, while non-GAAP gross margin reached 13.1%.

Akebia Therapeutics delivered a strong performance in Q2 2025, achieving a net income of $0.2 million, a substantial improvement from a net loss in the prior year. This turnaround was primarily fueled by a significant increase in total revenues to $62.5 million, largely due to the continued growth of Vafseo and increased Auryxia sales.

• Total revenues increased to $62.5 million in Q2 2025, up from $43.6 million in Q2 2024, driven by Vafseo's U.S. launch and increased Auryxia sales.
• Vafseo net product revenue reached $13.3 million in Q2 2025, with prescription demand growing approximately 55% over Q1 2025.

Olaplex delivered a solid first half of 2025, with net sales increasing by 2.3% to $106.3 million in Q2 2025 compared to the prior year. However, the company reported a net loss of $7.7 million and diluted EPS of ($0.01) for the quarter, a significant decrease from net income in Q2 2024.

• Net sales increased by 2.3% to $106.3 million in Q2 2025.
• The company reported a net loss of $7.7 million in Q2 2025, compared to a net income of $5.8 million in Q2 2024.

Collegium Pharmaceutical, Inc. delivered a strong second quarter in 2025, achieving record quarterly net revenue of $188.0 million, a 29% increase year-over-year. This growth was primarily driven by record Jornay PM net revenue and solid performance from its pain portfolio. The company also reported robust adjusted EBITDA and significant cash flow generation, leading to an upward revision of its full-year 2025 financial guidance.

• Record quarterly net revenue of $188.0 million, marking a 29% increase year-over-year.
• Jornay PM net revenue reached a record $32.6 million, with prescriptions growing 23% year-over-year.

Intellia Therapeutics reported a significant reduction in net loss for Q2 2025, decreasing to $101.3 million from $147.0 million in Q2 2024. Collaboration revenue increased, and operating expenses saw a notable decrease, primarily driven by lower R&D and G&A expenses. The company ended the quarter with a strong cash position, expected to fund operations into the first half of 2027.

• Net loss significantly decreased to $101.3 million in Q2 2025 from $147.0 million in Q2 2024.
• Collaboration revenue increased by 104.7% to $14.2 million in Q2 2025, primarily due to cost reimbursements from the Regeneron collaboration.

Wheels Up announced its second quarter 2025 results, with revenue decreasing by 3% year-over-year to $189.6 million. Despite the revenue dip, the company significantly improved its gross profit to $2.2 million, a $13.2 million improvement from the previous year's loss. Net loss also improved by 15% to $82.3 million, or $(0.12) per share, reflecting the company's strategic shift towards more profitable operations and fleet modernization.

• Revenue for Q2 2025 was $189.6 million, a 3% decrease year-over-year.
• Gross profit improved significantly to $2.2 million, a $13.2 million increase compared to a loss in the prior year.

Ecovyst delivered a solid second quarter in 2025, with sales increasing by 9.5% year-over-year to $200.1 million, driven by strong performance in the Ecoservices segment and the acquisition of Waggaman sulfuric acid assets. Despite the sales growth, net income decreased to $6.0 million from $8.3 million in the prior year, primarily due to higher costs and other operating expenses. Adjusted EBITDA was $55.7 million, at the high end of their guidance range, indicating strong operational performance.

• Total sales for Q2 2025 reached $200.1 million, a 9.5% increase from $182.8 million in Q2 2024.
• Net income for the quarter was $6.0 million, a decrease from $8.3 million in the same period last year, with diluted EPS at $0.05.

Altice USA's second quarter 2025 results demonstrated continued operational and financial momentum, with sequential and year-over-year improvements in broadband subscriber trends and ARPU growth. The company also saw significant expansion in fiber and mobile customer bases, alongside successful execution of efficiency initiatives and a strategic asset-backed loan.

• Broadband subscriber net losses improved year-over-year and sequentially, with total broadband subscribers reaching 4.3 million.
• Fiber customer base increased by 53% year-over-year to 663,000, and mobile lines grew by 42% year-over-year to 546,000.

Thermon Group Holdings, Inc. reported a revenue of $108.9 million for Q1 2026, a 5.4% decrease year-over-year, primarily due to reduced customer demand and delayed backlog conversion. Despite the revenue decline, the company achieved a net income of $8.6 million, a 1.2% increase, and an improved gross margin of 44.1%. Adjusted EBITDA decreased by 8.6% to $21.2 million. The company's backlog grew significantly by 27.1% to $252.2 million, and it maintained a strong net leverage ratio of 1.0x.

• Revenue for Q1 2026 decreased by 5.4% to $108.9 million, attributed to market uncertainty from tariffs and delayed backlog conversion.
• Net income increased by 1.2% to $8.6 million, and diluted EPS rose to $0.26, despite the revenue decline.

Avadel Pharmaceuticals delivered a robust performance in the second quarter of 2025, with LUMRYZ net revenue increasing by 64% year-over-year to $68.1 million. The company achieved a net income of $9.7 million and an EPS of $0.10, marking its first profitable quarter since the launch of LUMRYZ. Patient numbers for LUMRYZ also saw substantial growth, reaching 3,100 patients. The company raised its full-year 2025 revenue guidance to $265 - $275 million, reflecting strong commercial execution and market position.

• LUMRYZ net revenue reached $68.1 million in Q2 2025, a 64% increase compared to Q2 2024.
• Avadel Pharmaceuticals reported a net income of $9.7 million and diluted EPS of $0.10 for Q2 2025, the first profitable quarter since LUMRYZ's launch.

In Q2 2025, Zymeworks delivered $48,726,000 in revenue, reflecting a significant increase from the prior year, with net income of $2,317,000 and diluted EPS of $0.03, supported by milestone payments and royalty revenue from collaborations while maintaining strong cash resources of $333,400,000 at quarter end. :contentReference[oaicite:0]{index=0}

• Total revenue of $48,726,000 in Q2 2025, up sharply from Q2 2024. :contentReference[oaicite:1]{index=1}
• Net income of $2,317,000, reversing a net loss from the prior year. :contentReference[oaicite:2]{index=2}

QuinStreet delivered a robust performance in the fiscal fourth quarter of 2025, with revenue increasing by 32% year-over-year to $262.1 million. The company achieved GAAP net income of $3.2 million and adjusted net income of $14.7 million. Adjusted EBITDA saw a substantial 101% increase, reaching $22.1 million, driven by strong demand in Auto Insurance and Home Services.

• Q4 2025 revenue increased 32% year-over-year to $262.1 million, demonstrating strong growth.
• Adjusted EBITDA for Q4 2025 surged by 101% year-over-year to $22.1 million, indicating significant margin expansion.

nLIGHT, Inc. reported a strong second quarter in 2025, with revenues reaching $61.7 million, a 22.2% increase year-over-year. The company significantly improved its GAAP net loss and achieved non-GAAP net income, primarily driven by increased demand in its Aerospace & Defense segment.

• Total revenues for Q2 2025 were $61.7 million, up 22.2% from Q2 2024.
• Gross margin improved to 29.9% in Q2 2025 from 23.5% in Q2 2024.

FIGS delivered its largest revenue quarter in history, with net revenues growing 5.8% year-over-year to $152.6 million. The company achieved a net income margin of 4.7% and an adjusted EBITDA margin of 12.9%, demonstrating strong execution and profitability. This performance has led to an increased full-year 2025 outlook.

• Net revenues increased by 5.8% year-over-year, reaching $152.6 million, marking the largest revenue quarter in company history.
• Net income margin improved significantly to 4.7%, and adjusted EBITDA margin reached 12.9%, indicating strong profitability.

indie Semiconductor reported Q2 2025 revenue of $51630000 and a GAAP net loss, with non-GAAP loss per share improved, surpassing the midpoint of its outlook and advancing strategic initiatives in ADAS and vision technologies. :contentReference[oaicite:0]{index=0}

• Revenue was $51630000 for the quarter, above the midpoint of guidance. :contentReference[oaicite:1]{index=1}
• GAAP net loss was significant with a loss per share of $0.20. :contentReference[oaicite:2]{index=2}

Granite Ridge Resources, Inc. delivered a robust second quarter in 2025, with daily production increasing by 37% year-over-year to 31,576 Boe per day. The company reported a net income of $25.1 million and generated $75.4 million in Adjusted EBITDAX. Capital expenditures were focused on development and strategic acquisitions, and a quarterly cash dividend of $0.11 per share was declared.

• Daily production increased by 37% year-over-year to 31,576 Boe per day, with oil production rising 46% and natural gas production rising 28%.
• Net income significantly improved to $25.1 million, or $0.19 per diluted share, compared to $5.1 million in the prior year period.

AMN Healthcare experienced a challenging second quarter in 2025, with consolidated revenue decreasing by 11% year-over-year to $658 million and a GAAP net loss of $116.2 million, largely driven by $128 million in non-cash goodwill and intangible asset impairment charges. Despite the GAAP loss, adjusted diluted EPS was $0.30, and adjusted EBITDA was $58.3 million, both showing significant year-over-year declines. The company noted that allied staffing performed well, exceeding projections, and strong cash flow from operations allowed for debt reduction.

• Consolidated revenue for Q2 2025 was $658 million, an 11% decrease from the prior year.
• The company reported a GAAP net loss of $116.2 million, or ($3.02) per diluted share, primarily due to $128 million in non-cash impairment charges.

Willdan Group delivered a robust second quarter in 2025, showcasing double-digit growth in net revenue and adjusted EBITDA, alongside triple-digit growth in earnings per share. These strong results were driven by consistent execution, new contract wins, and successful strategic acquisitions, leading the company to raise its full-year financial targets.

• Contract revenue increased by 23.0% to $173.5 million in Q2 2025.
• Net revenue grew by 31.1% to $95.0 million, reflecting strong operational performance.

Blend reported a strong second quarter in 2025, achieving its fourth consecutive quarter of year-over-year revenue growth and non-GAAP operating profit. The company saw accelerated sales momentum with 23 new or expanded deals, more than doubling the first quarter's deal count, and ended the quarter with a record remaining performance obligations (RPO) balance of $190.4 million. GAAP loss from operations significantly improved, and non-GAAP diluted net income per share reached $0.00.

• Blend achieved its fourth consecutive quarter of year-over-year revenue growth and non-GAAP operating profit.
• Sales momentum accelerated in Q2 2025 with 23 new or expanded deals, more than double the previous quarter.

NerdWallet delivered a strong second quarter in 2025, achieving $186.9 million in revenue, a 24% increase year-over-year, driven by robust growth in Insurance and Emerging Verticals. The company also significantly improved its profitability, reporting GAAP income from operations of $10.7 million and non-GAAP operating income of $20.7 million, demonstrating effective operational efficiency.

• Total revenue reached $186.9 million, marking a 24% increase compared to the same quarter last year.
• GAAP income from operations was $10.7 million, a significant improvement from a loss in the prior year.

Liquidity Services achieved record Gross Merchandise Volume (GMV) and significant increases in revenue, net income, and EPS for Q3 FY2025. The company's strategic investments in technology and a diversified business model contributed to its strong performance across all segments, despite some economic uncertainties.

• Record Gross Merchandise Volume (GMV) reached $413.0 million, marking a 9% increase year-over-year.
• Total revenue grew by 28% to $119.9 million, compared to $93.6 million in the prior year's quarter.

Phathom Pharmaceuticals delivered strong sequential revenue growth in Q2 2025, driven by the continued commercial launch of VOQUEZNA products. The company reported net revenues of $39.5 million, a substantial increase from the previous year, and reduced its net loss. Strategic cost reductions and a refined commercial strategy focusing on high-value prescribers are positioning the company for profitability in 2026.

• Net revenues for Q2 2025 reached $39.5 million, a significant increase of $32.2 million compared to Q2 2024.
• Over 580,000 VOQUEZNA prescriptions have been filled to date, with approximately 173,000 filled in Q2 2025, representing 36% sequential growth.

Xeris Biopharma achieved record financial results in Q2 2025, with total revenue increasing by 49% year-over-year to $71.5 million, primarily fueled by a 136% surge in Recorlev revenue. The company also raised its full-year 2025 revenue guidance, reflecting strong patient demand and confidence in continued growth.

• Total revenue for Q2 2025 reached a record $71.5 million, marking a 48.8% increase year-over-year.
• Recorlev revenue significantly grew by 135.7% to $31.4 million, driven by a 122% increase in the average number of patients.

FTAI Infrastructure Inc. reported a significant net loss attributable to stockholders of $79.8 million for the second quarter of 2025, with a basic and diluted loss per share of $0.73. Despite the loss, the company achieved an Adjusted EBITDA of $45.9 million, and $52.6 million from its four core segments, indicating operational strength excluding certain non-GAAP adjustments. Key business highlights included an agreement to acquire the Wheeling & Lake Erie Railway for $1.05 billion and the closing of $300 million in tax-exempt debt financing for the Repauno facility.

• Net loss attributable to stockholders was $79.8 million for Q2 2025, a significant increase from the $54.35 million loss in Q2 2024.
• Basic and diluted loss per share of common stock was $0.73, compared to $0.52 in the prior year's quarter.

Target Hospitality experienced a significant decline in revenue and reported a net loss in Q2 2025, largely due to the termination of major government contracts. Despite these challenges, the company made substantial progress in strategic diversification, securing over $400 million in new multi-year contracts and raising its full-year 2025 outlook.

• Revenue for Q2 2025 decreased to $61.6 million from $100.7 million in Q2 2024, primarily due to government contract terminations.
• The company reported a net loss of $14.9 million and a basic and diluted loss per share of $0.15 for Q2 2025.

Iovance Biotherapeutics reported strong product revenue growth in Q2 2025, primarily driven by the U.S. launch of Amtagvi, which surpassed 100 patients treated in the quarter. The company also announced a strategic restructuring to extend its cash runway into Q4 2026 and reiterated its full-year 2025 total product revenue guidance.

• Total product revenue reached $60.0 million in Q2 2025, a 93% increase year-over-year.
• Amtagvi sales in the U.S. were $54.1 million, with over 100 commercial patients treated.

GigaCloud Technology Inc reported a strong second quarter in 2025, achieving record quarterly revenue of $322.6 million, a 3.8% increase year-over-year. The company saw significant growth in net income, up 28.1% to $34.6 million, and diluted EPS, which increased 40.0% to $0.91. Gross profit also saw a slight increase, while adjusted EBITDA grew by 1.4%. The company's Noble House portfolio contributed meaningfully to margins, and strategic investments in acquisitions and share repurchases underscore a focus on shareholder value.

• Total revenues reached a record $322.6 million in Q2 2025, marking a 3.8% increase year-over-year.
• Net income significantly increased by 28.1% year-over-year to $34.6 million, with diluted EPS rising 40.0% to $0.91.

Metallus delivered strong second-quarter 2025 results, with net sales reaching $304.6 million and net income of $3.7 million. Adjusted net income was $8.4 million, and adjusted EBITDA significantly improved to $26.5 million. The company saw increased shipments across key end markets and improved melt utilization, while maintaining a strong liquidity position and investing in strategic initiatives.

• Net sales increased to $304.6 million, a 9% sequential increase and 3% increase compared to the prior year, driven by higher shipments and raw material surcharge revenue.
• Net income was $3.7 million, with adjusted net income at $8.4 million, reflecting significant improvement in profitability.

i3 Verticals delivered a strong third quarter for fiscal year 2025, with revenue from continuing operations increasing by 12.4% year-over-year to $51.9 million. The company significantly reduced its net loss from continuing operations to $1.0 million from $14.4 million in the prior year, and adjusted EBITDA from continuing operations grew by 18.0% to $12.7 million. This performance was primarily driven by growth in recurring contracts, particularly SaaS and payments revenue.

• Third quarter revenue from continuing operations increased by 12.4% to $51.9 million compared to the prior year.
• Net loss from continuing operations significantly decreased to $1.0 million from $14.4 million in the prior year's third quarter.

Nextdoor delivered a strong second quarter in 2025, with revenue increasing 3% year-over-year to $65 million and Platform Weekly Active Users (WAU) growing 1% to 21.8 million. The company significantly reduced its net loss to $15 million from $43 million in the prior year and improved its Adjusted EBITDA loss to $2 million from $6 million, demonstrating a 6 percentage point margin improvement. Nextdoor also announced a restructuring plan to reduce annualized operating expenses by approximately $30 million, aiming for quarterly adjusted EBITDA breakeven in Q4 2025 and full-year adjusted EBITDA breakeven in FY 2026.

• Revenue for Q2 2025 reached $65 million, marking a 3% increase year-over-year.
• Platform Weekly Active Users (WAU) grew to 21.8 million, up 1% compared to the same period last year.

The RealReal delivered a breakout performance in the second quarter of 2025, achieving record high quarterly Gross Merchandise Value (GMV) and total revenue, both increasing by 14% year-over-year. The company significantly improved its net loss and adjusted EBITDA, demonstrating the success of its strategic roadmap and operational efficiency.

• Total Revenue reached $165 million, marking a 14% increase compared to Q2 2024.
• Net Loss improved to $(11) million, a $5 million improvement year-over-year.

Westrock Coffee Company delivered a strong second quarter in 2025, with consolidated net sales increasing by 34.8% to $280.9 million. Despite a flat gross profit compared to the prior year, the company saw significant growth in Consolidated Adjusted EBITDA, reaching $15.3 million, up from $12.4 million in Q2 2024. Both Beverage Solutions and Sustainable Sourcing & Traceability segments reported record performance, driven by the successful launch of new facilities and production ramp-ups.

• Consolidated net sales increased by 34.8% to $280.9 million in Q2 2025.
• Consolidated Adjusted EBITDA grew to $15.3 million, including $7.6 million in scale-up costs for the Conway Facility.

For the three months ended June 30, 2025, Armada Hoffler generated $101.263 million of total revenue and $3.062 million of net income attributable to common stockholders. Operating income was $19.968 million. Normalized FFO was $25.390 million, or $0.25 per diluted share.

• Total revenue was $101.263 million for the quarter.
• Net income attributable to common stockholders was $3.062 million ($0.04 per share).

RxSight reported a 4% decrease in total revenue to $33.6 million in Q2 2025 compared to the previous year, primarily due to a significant 50% decline in Light Delivery Device (LDD) revenue, despite a 13% increase in Light Adjustable Lens (LAL) revenue. The company experienced a net loss of $(11.8) million, or $(0.29) per share, widening from a net loss of $(6.1) million in Q2 2024. Gross profit improved to $25.2 million, or 74.9% of revenue, driven by a favorable shift towards LAL sales.

• Total revenue for Q2 2025 was $33.6 million, a 4% decrease from $34.9 million in Q2 2024.
• Light Adjustable Lens (LAL) sales increased by 13%, while Light Delivery Device (LDD) sales decreased by 50% compared to the second quarter of 2024.

Legacy Housing Corporation reported a strong second quarter in 2025 with net revenue increasing by 18.0% to $50.2 million and income from operations rising by 4.9% to $16.8 million. However, net income decreased by 9.2% to $14.7 million, and basic earnings per share fell by 9.0% to $0.61. The company also saw an 11.2% increase in book value per share to $21.32 and repurchased $5.8 million worth of common stock.

• Net revenue for Q2 2025 increased by 18.0% to $50.2 million, driven by higher average selling prices and increased unit volumes.
• Income from operations rose by 4.9% to $16.8 million in Q2 2025.

For the three months ended June 30, 2025, Advantage Solutions reported revenue of 873707000, essentially flat year-over-year. The company narrowed its net loss to 30440000 and delivered Adjusted EBITDA of 86412000, with margin compression compared to the prior year. Liquidity remained solid with approximately 103000000 in cash.

• Revenue was flat year-over-year at 873707000.
• Net loss narrowed significantly to 30440000 from prior year.

Consensus Cloud Solutions delivered a strong Q2 2025, with total revenues increasing by 0.3% to $87.7 million, primarily due to a 6.9% growth in the Corporate business. Despite a planned decrease in the SoHo segment, the company maintained robust operating margins, leading to strong cash flows. Net income and EPS saw a decrease, mainly due to foreign exchange fluctuations, but adjusted net income and adjusted EPS increased.

• Total revenues increased by 0.3% to $87.7 million in Q2 2025, compared to $87.5 million in Q2 2024, marking a return to positive revenue growth.
• Corporate revenue grew by 6.9% to $55.3 million, driven by strong usage, improved revenue retention, and new customer acquisition.

Ginkgo Bioworks demonstrated strong commercial traction in Q2 2025, driven by growing demand for its AI in biology platform, securing new government contracts, and expanding biopharma service offerings. The company also successfully achieved its $250 million annualized cost-reduction goal three months ahead of schedule, reflecting rigorous financial discipline.

• Total revenue for Q2 2025 was $49.604 million, a decrease from $56.206 million in Q2 2024.
• Net loss significantly improved to $(60.300) million in Q2 2025, compared to $(217.181) million in Q2 2024.

Aspen Aerogels experienced a challenging second quarter in 2025 with total revenue of $78.0 million, a decrease from the prior year. Despite a net loss of $9.1 million, the company showed significant improvement in gross margins at 32% and nearly doubled its Adjusted EBITDA quarter-over-quarter to $9.7 million, driven by cost structure reductions and strategic streamlining efforts.

• Total revenue for Q2 2025 was $78.0 million, a decrease from $117.8 million in Q2 2024.
• The company reported a net loss of $9.1 million, which included $5.9 million in restructuring and impairment charges.

Cullinan Therapeutics reported a net loss of $70.1 million for Q2 2025, an increase from $42.0 million in Q2 2024, primarily driven by a significant rise in research and development expenses to $61.0 million. The company maintained a strong cash position of $510.9 million, providing a runway into 2028.

• Research and development expenses significantly increased to $61.0 million in Q2 2025 from $36.3 million in Q2 2024, reflecting increased pipeline activity.
• The net loss attributable to Cullinan widened to $70.1 million in Q2 2025, compared to $42.0 million in the same period last year.

Amylyx Pharmaceuticals reported a net loss of $41.4 million for Q2 2025, an improvement from the $72.7 million net loss in Q2 2024. The company had no product revenue for the quarter. Research and development expenses increased, while selling, general, and administrative expenses decreased. The company maintains a strong cash position of $180.8 million, with a cash runway expected through the end of 2026.

• Net loss for Q2 2025 was $41.4 million, a significant reduction from $72.7 million in Q2 2024.
• The company reported no product revenue for the second quarter of 2025.

BlackSky reported a decrease in total revenue for Q2 2025 compared to the previous year, primarily due to a decline in professional and engineering services revenue. Despite this, imagery and software analytical services revenue saw a slight increase. The company's net loss widened significantly, largely due to a loss on derivatives. Adjusted EBITDA also saw a decrease, moving from a gain in the prior year to a loss in the current quarter. The company strengthened its balance sheet with a successful $185 million convertible note offering subsequent to the quarter end.

• Total revenue for Q2 2025 was $22.2 million, a decrease from $24.9 million in Q2 2024.
• Net loss for the quarter was $41.2 million, a substantial increase from a $9.4 million net loss in the prior year, mainly due to a $24.4 million loss on derivatives.

Clean Energy Fuels Corp. reported a revenue increase to $102.6 million in Q2 2025 from $98.0 million in Q2 2024. Despite the revenue growth, the company experienced a net loss of $(20.2) million, or $(0.09) per share, and a decrease in Adjusted EBITDA to $17.5 million. RNG gallons sold increased by 7.5% to 61.4 million gallons.

• Revenue increased to $102.6 million in Q2 2025, up from $98.0 million in Q2 2024.
• Net loss attributable to Clean Energy was $(20.2) million, or $(0.09) per share, in Q2 2025, compared to $(16.3) million, or $(0.07) per share, in Q2 2024.

Organogenesis Holdings Inc. reported a net product revenue of $100.8 million for the second quarter of 2025, a 23% decrease year-over-year. The company experienced a net loss of $9.4 million, which was an improvement from the $17.0 million net loss in the same period last year. Advanced Wound Care product revenue decreased significantly, while Surgical & Sports Medicine products saw an increase.

• Net product revenue for Q2 2025 was $100.8 million, a 23% decrease from $130.2 million in Q2 2024.
• The company reported a net loss of $9.4 million in Q2 2025, an improvement from a $17.0 million net loss in Q2 2024.

Definitive Healthcare reported second-quarter revenue of $60.8 million, a 5% decrease year-over-year, but exceeded its guidance. The company achieved a net loss of $(9.3) million, a significant improvement from the prior year's $(306.2) million loss which included substantial goodwill impairment. Adjusted Net Income was $9.7 million and Adjusted EBITDA was $18.7 million, representing a 31% margin. Cash Flow from Operations was $9.3 million, and Unlevered Free Cash Flow was $11.5 million.

• Revenue for Q2 2025 was $60.8 million, exceeding the company's guidance.
• Net loss significantly improved to $(9.3) million in Q2 2025 from $(306.2) million in Q2 2024, primarily due to the absence of large goodwill impairment charges.

The Manitowoc Company reported a net income of $1.5 million for the second quarter of 2025, or $0.04 per diluted share. While net sales decreased by 4.0% year-over-year to $539.5 million, orders saw a 6.0% increase to $453.9 million, driven by strong performance in the MGX distribution business and European tower crane market. Adjusted EBITDA decreased by 26.9% to $26.3 million.

• Orders increased by 6.0% year-over-year to $453.9 million, indicating strong demand.
• Net sales decreased by 4.0% year-over-year to $539.5 million, primarily due to tariff headwinds.

VAALCO Energy, Inc. announced strong second quarter 2025 results, with net income of $8.4 million and adjusted EBITDAX of $49.9 million. The company's net revenue interest (NRI) production of 16,956 barrels of oil equivalent per day (BOEPD) was above the high end of guidance, and sales volumes also exceeded expectations. The company reiterated its full-year guidance, including a 10% reduction in capital expenditures without impacting production or sales targets.

• Reported net income of $8.4 million ($0.08 per diluted share) and Adjusted EBITDAX of $49.9 million.
• Produced 16,956 net revenue interest (NRI) BOEPD, above the high end of guidance, and sold 19,393 NRI BOEPD, also above the high end of guidance.

Jumia reported a strong second quarter in 2025, with revenue increasing by 25% year-over-year to $45.6 million and a notable reduction in operating loss to $16.5 million. The company also saw a significant improvement in cash burn and raised its full-year 2025 guidance, reinforcing its confidence in achieving profitability targets.

• Revenue grew by 25% year-over-year to $45.6 million, driven by strong performance in both marketplace and first-party sales.
• Operating loss decreased by 18% year-over-year to $16.5 million, indicating improved operational efficiency.

Kelly Services reported second-quarter 2025 revenue of $1.1 billion, a 4.2% increase year-over-year, primarily due to the acquisition of Motion Recruitment Partners, LLC. However, organic revenue declined by 3.3%. Operating earnings significantly increased to $22.2 million, while adjusted EBITDA decreased by 8.7% to $37.0 million, with the adjusted EBITDA margin falling to 3.4%. Diluted EPS was $0.52, and adjusted diluted EPS was $0.54.

• Revenue for Q2 2025 increased by 4.2% year-over-year to $1.1 billion, primarily driven by the Motion Recruitment Partners acquisition.
• Operating earnings saw a substantial increase to $22.2 million in Q2 2025, up from $12.2 million in the prior year.

Runway Growth Finance Corp. delivered consistent earnings power in Q2 2025, with total investment income of $35.1 million and net investment income of $13.9 million, or $0.38 per share. The company expanded its origination channels and enhanced its solutions set, optimizing its portfolio through diversification and maximizing existing commitments. The investment portfolio reached $1.0 billion, and the company maintained strong liquidity.

• Total investment income for Q2 2025 was $35.1 million, an increase from $34.2 million in Q2 2024.
• Net investment income was $13.9 million, or $0.38 per share, compared to $14.6 million, or $0.37 per share, in the prior year.

PacBio demonstrated a strong performance in Q2 2025, achieving revenue growth both sequentially and year-over-year, reaching $39.8 million. The company significantly reduced its GAAP net loss to $41.9 million from $173.3 million in the prior year, and improved its non-GAAP net loss to $40.0 million. This positive trend was supported by disciplined cost management and increased adoption of its HiFi sequencing platforms.

• Total revenue increased to $39.8 million in Q2 2025, up from $36.0 million in Q2 2024, marking both sequential and year-over-year growth.
• GAAP net loss significantly narrowed to $41.9 million in Q2 2025, a substantial improvement from a $173.3 million loss in Q2 2024.

Eton Pharmaceuticals delivered impressive second-quarter results, with total net revenues reaching $18.9 million, a 108% increase year-over-year, primarily fueled by strong product sales of ALKINDI SPRINKLE, INCRELEX, and GALZIN. The company achieved non-GAAP diluted EPS of $0.03 and significantly improved its Adjusted EBITDA to $3.1 million. Key operational successes included the FDA approval and launch of KHINDIVI, reaching 100 active INCRELEX patients ahead of schedule, and advancing its pipeline programs.

• Total net revenues for Q2 2025 were $18.9 million, marking a 108% increase compared to Q2 2024.
• Product sales and royalties reached $18.9 million, representing the 18th consecutive quarter of sequential growth.

Treace Medical Concepts delivered solid financial results in the second quarter of 2025, with revenue increasing by 7% year-over-year to $47.4 million. The company significantly improved its net loss by 18% and adjusted EBITDA by 58%, demonstrating progress in its strategic initiatives and expanded product portfolio.

• Revenue for Q2 2025 reached $47.4 million, marking a 7% increase compared to Q2 2024.
• Net loss improved by 18% to $(17.4) million in Q2 2025, down from $(21.2) million in Q2 2024.

Ambac Financial Group, Inc. reported strong growth in its P&C business for the second quarter of 2025, with total revenue from continuing operations increasing by 8% to $55 million and total P&C premium production surging by 110% to $346 million. The company also noted that the Wisconsin OCI recommended approval for the sale of AAC, with a hearing scheduled for September 3rd, 2025.

• Total revenue from continuing operations increased 8% to $55 million for the quarter.
• Total P&C premium production grew by 110% to $346 million for the quarter.

Corvus Pharmaceuticals reported a net loss of $8.0 million for Q2 2025, an increase from $4.3 million in Q2 2024, primarily due to higher research and development expenses. The company's cash position significantly improved to $74.4 million, bolstered by $35.7 million from warrant exercises, extending its cash runway into Q4 2026. Key clinical advancements include positive Phase 1 data for soquelitinib in atopic dermatitis and ongoing enrollment in Phase 3 PTCL and Phase 2 ALPS trials.

• Net loss for Q2 2025 was $8.0 million, compared to a net loss of $4.3 million for the same period in 2024.
• Research and development expenses increased to $7.9 million in Q2 2025 from $4.1 million in Q2 2024, driven by higher clinical trial and manufacturing costs for soquelitinib.

Kaltura exceeded its second-quarter guidance, achieving record non-GAAP net profit and strong operating cash flow. The company reported a 1% increase in total revenue to $44.5 million and a significant reduction in GAAP net loss. Strategic reorganization and AI product sales are key drivers for future growth and efficiency.

• Total revenue for Q2 2025 was $44.5 million, a 1% increase year-over-year.
• GAAP net loss significantly improved to $7.8 million, down from $10.0 million in Q2 2024.

Chicago Atlantic Real Estate Finance reported a net income of $8.88 million and diluted EPS of $0.41 for Q2 2025. The company maintained a disciplined focus on its cannabis loan portfolio and extended its revolving credit facility to 2028, positioning itself for future growth opportunities within its substantial pipeline.

• Net income for Q2 2025 was $8.88 million, with diluted earnings per share at $0.41.
• The company successfully extended its secured revolving credit facility maturity from June 30, 2026, to June 30, 2028.

Rackspace Technology reported a revenue of $666 million in Q2 2025, a 3% decrease year-over-year. The company experienced a net loss of $55 million and a diluted EPS of $(0.23). Despite the revenue decline, Non-GAAP Operating Profit increased by 34% to $27 million, and bookings grew by 16%, indicating strong go-to-market execution and progress in their turnaround strategy.

• Revenue for Q2 2025 was $666 million, a 3% decrease year-over-year, but exceeded the midpoint of guidance.
• The company reported a net loss of $55 million and a diluted EPS of $(0.23) for the quarter.

Backblaze reported a strong second quarter in 2025, achieving $36.3 million in revenue, a 16% year-over-year increase. The company significantly reduced its net loss to $7.1 million and achieved a non-GAAP net income of $0.8 million. B2 Cloud Storage revenue grew by an impressive 29% year-over-year, driving overall performance and solidifying the company's path towards becoming Adjusted Free Cash Flow positive.

• Total revenue reached $36.3 million, marking a 16% increase year-over-year.
• B2 Cloud Storage revenue surged by 29% year-over-year to $19.8 million.

Funko experienced a challenging second quarter in 2025, with net sales significantly declining to $193.5 million from $247.7 million in the prior year. The company reported a net loss of $41.0 million, or $0.74 per share, a substantial shift from a net income of $5.4 million in Q2 2024. Adjusted net loss was $26.7 million, and adjusted EBITDA was negative $16.5 million, primarily attributed to a dynamic and uncertain tariff environment.

• Net sales for Q2 2025 decreased by 21.9% to $193.5 million from $247.7 million in Q2 2024.
• The company reported a net loss of $41.0 million, or $0.74 per share, a significant decline from a net income of $5.4 million, or $0.10 per share, in the same period last year.

Lifecore Biomedical experienced a 4% decrease in Q4 2025 revenue to $36.4 million, primarily due to lower CDMO development revenue, though HA manufacturing revenue increased. The company significantly reduced its net loss to $1.1 million from $7.1 million in the prior year, driven by a gain from a legacy business obligation settlement and favorable debt derivative adjustment. For the full fiscal year, revenue reached $128.9 million, meeting guidance, but the company reported a net loss of $38.7 million.

• Fourth-quarter revenue decreased by 4% to $36.4 million, primarily due to a $5.6 million decrease in CDMO revenues, partially offset by a $4.1 million increase in HA manufacturing revenues.
• Net loss for Q4 significantly improved to $1.1 million ($0.06 per diluted share) from $7.1 million ($0.19 per diluted share) in the prior year, benefiting from a legacy business obligation settlement and a favorable debt derivative adjustment.

Health Catalyst delivered a strong performance in Q2 2025, with total revenue reaching $80.7 million and Adjusted EBITDA at $9.3 million, both surpassing the company's guidance. Despite a significant net loss, the company's core operational metrics showed positive growth.

• Total revenue for Q2 2025 was $80.7 million, marking a 6% increase year-over-year.
• Adjusted EBITDA reached $9.3 million in Q2 2025, a 24% increase compared to the same period last year.

ATN International reported second-quarter 2025 results that aligned with expectations, despite a 1% decline in revenues to $181.3 million and a significant decrease in operating income to $0.2 million, primarily due to the absence of a large gain from asset disposition seen in the prior year. The company posted a net loss of $(7.0) million, or $(0.56) per share, and Adjusted EBITDA decreased by 6% to $45.8 million. Despite these declines, ATN reaffirmed its full-year 2025 outlook, emphasizing cost optimization and strategic execution.

• Second-quarter revenues decreased by 1% to $181.3 million compared to the prior year.
• Operating income significantly declined to $0.2 million from $24.3 million in the year-ago quarter, largely due to a prior-year gain on asset disposition.

Forum Energy Technologies delivered robust second quarter 2025 results, achieving $200 million in revenue and $8 million in net income. The company reported its eighth consecutive quarter of positive free cash flow and significantly increased its full-year free cash flow guidance to between $60 million and $80 million, driven by strong bookings and operational improvements.

• Revenue for Q2 2025 was $200 million, marking a 3% sequential increase.
• Net income reached $8 million, or $0.61 per diluted share, for the quarter.

Eventbrite delivered net revenue of $72.8 million, which was at the top end of its guidance, despite a 14% year-over-year decline. The company reported a net loss of $2.1 million but achieved an Adjusted EBITDA margin of 8.8%, significantly exceeding expectations. Key operational metrics like paid ticket volume and paid creators showed continued improvement in year-over-year trends.

• Net revenue reached $72.8 million, aligning with the high end of the company's outlook range, despite a 14% year-over-year decline.
• The company reported a net loss of $2.1 million, a significant decrease compared to a net income of $1.1 million in the prior year, which included a legal settlement gain.

OptimizeRx delivered a robust second quarter in 2025, with revenue increasing by 55% year-over-year to $29.2 million and gross profit rising by 59% to $18.6 million. The company achieved GAAP net income of $1.5 million and non-GAAP net income of $4.5 million, demonstrating a significant turnaround from a net loss in the prior year. OptimizeRx also strengthened its financial position by paying down $4.5 million of principal on its outstanding term loan and raised its full-year 2025 guidance for both revenue and adjusted EBITDA.

• Revenue for Q2 2025 increased by 55% year-over-year, reaching $29.2 million.
• Gross profit for Q2 2025 grew by 59% year-over-year to $18.6 million.

Quanterix experienced a challenging second quarter in 2025, with total revenue decreasing by 29% year-over-year to $24.5 million and a net loss of $30.0 million, significantly wider than the $7.4 million loss in the prior year. Despite these financial setbacks, the company completed the acquisition of Akoya Biosciences and made progress on cost reduction targets, aiming for cash flow breakeven in 2026.

• Total revenue for Q2 2025 was $24.5 million, a 29% decrease from $34.4 million in Q2 2024.
• The company reported a net loss of $30.0 million in Q2 2025, compared to a net loss of $7.4 million in the same period last year.

TTEC announced solid financial results for the second quarter of 2025, with revenue of $513.6 million. The company reported a GAAP net loss of $6.7 million, but a non-GAAP net income of $10.6 million. Income from operations saw a substantial improvement, reaching $18.9 million compared to a loss in the prior year, driven by the absence of large impairment charges. Adjusted EBITDA also increased, reflecting improved profitability.

• Revenue for Q2 2025 was $513.6 million, a 3.8% decrease year-over-year.
• GAAP income from operations significantly improved to $18.9 million (3.7% of revenue) from a loss of $224.4 million in the prior year, primarily due to the absence of non-cash impairment charges.

ON24 reported a strong second quarter in 2025, surpassing expectations with total revenue of $35.3 million. The company achieved its sixth consecutive quarter of positive operating and free cash flow, alongside record-high gross retention and an increased percentage of ARR from multi-year agreements. These results indicate significant improvements across key financial and customer metrics compared to the previous year, positioning ON24 for ARR growth by year-end.

• Total revenue reached $35.3 million, exceeding expectations for the quarter.
• Achieved positive operating cash flow of $2.6 million and free cash flow of $2.1 million for the sixth consecutive quarter.

Sight Sciences reported a total revenue of $19.6 million for Q2 2025, an 8% decrease year-over-year, primarily due to lower Surgical Glaucoma revenue impacted by Medicare coverage restrictions. Despite this, the company reduced operating expenses and saw an increase in Surgical Glaucoma ordering accounts, leading to a slightly improved net loss.

• Total revenue for Q2 2025 was $19.6 million, an 8% decrease compared to the prior year, mainly due to a decline in the Surgical Glaucoma segment.
• Operating expenses were reduced by 9% to $28.3 million in Q2 2025, primarily due to lower legal expenses.

Beauty Health delivered a strong performance in Q2 2025, exceeding revenue and Adjusted EBITDA expectations. The company reported net sales of $78.2 million and a net income of $19.7 million, a significant increase from the prior year. This was primarily driven by strong consumables sales and improved gross margins, despite a decrease in delivery systems sales.

• Net sales for Q2 2025 were $78.2 million, a decrease of 13.7% compared to Q2 2024, primarily due to lower delivery systems net sales.
• Gross margin significantly improved to 62.8% in Q2 2025 from 45.2% in Q2 2024, driven by lower inventory charges and a favorable mix shift towards consumables.

scPharmaceuticals demonstrated strong performance in Q2 2025, driven by a 99% increase in FUROSCIX net revenue to $16 million. The company also saw a substantial rise in doses filled and expanded into the chronic kidney disease market, while maintaining a solid cash position.

• Net FUROSCIX revenue reached $16 million in Q2 2025, marking a 99% increase compared to Q2 2024.
• Approximately 20,200 FUROSCIX doses were filled, representing a 117% annual growth.

Nerdy reported Q2 2025 revenue of $45.3 million, within guidance, despite an 11% year-over-year decrease primarily due to lower Institutional revenue and the non-recurrence of a specific state-funded consumer program. The company saw a return to growth in Consumer Learning Membership revenue and beat its Non-GAAP Adjusted EBITDA Loss guidance, reinforcing its path to profitability by Q4 2025.

• Revenue for Q2 2025 was $45.3 million, aligning with guidance but down 11% year-over-year.
• Consumer Learning Membership revenue increased 4% year-over-year, reaching $37.8 million and representing 84% of total revenue.

Perma-Fix Environmental Services, Inc. delivered sequential and year-over-year revenue growth in Q2 2025, reaching $14.6 million, primarily driven by a 37% increase in the Treatment Segment revenue. The company also saw improved gross profit and a reduced net loss compared to the previous year, despite challenges in the Services Segment and initial production issues in the Treatment Segment.

• Revenue for Q2 2025 increased to $14.6 million, up from $14.0 million in Q2 2024, showing both sequential and year-over-year growth.
• The Treatment Segment revenue significantly grew by 37% year-over-year, reaching $11.4 million, driven by increased waste volume and higher average waste prices.

Aldeyra reported a significant reduction in net loss for Q2 2025 as it curtailed research and administrative costs, maintaining a healthy cash position despite continued development-stage losses.

• Net loss was $9.77 million in Q2 2025, an improvement from $16.85 million in Q2 2024.
• R&D expenses dropped by 43% YoY, reflecting lower clinical and manufacturing costs.

Inogen delivered strong second quarter 2025 financial results, with total revenue reaching $92.3 million, a 4.0% increase year-over-year. The company reported a GAAP net loss of $4.2 million but achieved positive adjusted EBITDA of $2.1 million for the second consecutive quarter. This performance led to an increase in full-year 2025 revenue guidance.

• Achieved second quarter 2025 revenue of $92.3 million, a 4.0% year-over-year increase, marking the sixth consecutive quarter of mid-single-digit percentage growth.
• Delivered adjusted EBITDA of $2.1 million, representing the second consecutive quarter of positive adjusted EBITDA.

The Joint Corp. demonstrated progress in its multi-year strategy during Q2 2025, with a 5% increase in revenue to $13.3 million and a substantial turnaround in consolidated net income to $93,000 from a $3.6 million loss in Q2 2024. The company continued its transition to a pure-play franchisor model, with franchised clinics now representing 92% of its portfolio.

• Revenue increased by 5% to $13.3 million in Q2 2025, up from $12.6 million in Q2 2024.
• Consolidated net income improved significantly to $93,000, compared to a net loss of $3.6 million in the prior year's quarter.

Ventyx Biosciences reported a net loss of $27.0 million for Q2 2025, an improvement from $32.0 million in Q2 2024. The company's R&D and G&A expenses both decreased, contributing to a lower total operating loss. Ventyx maintains a strong cash position of $209.0 million, expected to fund operations into at least H2 2026, and has made significant progress in its Phase 2 clinical trials for VTX3232 and VTX2735.

• Net loss improved to $27.0 million in Q2 2025 from $32.0 million in Q2 2024.
• Research and Development (R&D) expenses decreased to $22.3 million, down from $27.8 million in the prior year quarter.

Puma Biotechnology delivered a robust performance in Q2 2025, with total revenue reaching $52.4 million, up from $47.1 million in Q2 2024. The company achieved a net income of $5.9 million, a substantial turnaround from a net loss of $4.5 million in the same period last year. This positive shift was primarily fueled by increased product revenue from NERLYNX® and reduced selling, general, and administrative expenses.

• Total revenue for Q2 2025 increased to $52.4 million, up from $47.1 million in Q2 2024, primarily due to higher product and royalty revenue.
• The company reported a net income of $5.9 million ($0.12 per share) in Q2 2025, a significant improvement from a net loss of $4.5 million ($0.09 per share) in Q2 2024.

DocGo reported a significant decline in total revenue for Q2 2025, primarily due to the planned wind-down of migrant-related programs. Despite this, the company increased its cash balance and made progress in expanding its payer and provider business, signing new contracts across all business verticals. The net loss widened compared to the previous year, and adjusted EBITDA turned negative.

• Total revenue for Q2 2025 was $80.4 million, a substantial decrease from $164.9 million in Q2 2024, mainly due to the wind-down of migrant-related programs.
• The company reported a net loss of $13.3 million for Q2 2025, compared to a net income of $5.9 million in Q2 2024.

Revenue was $1.78M, down from $2.77M YoY, driven by reduced licensing income. Net loss widened to $15.43M due to increased R&D spending on bosakitug and ATI-052 trials. Operating loss was $18.41M. Cash, cash equivalents, and marketable securities totaled $180.89M, providing runway into H2 2028.

• Total revenue of $1.78M decreased from $2.77M in Q2 2024, primarily due to lower licensing income.
• R&D expenses rose to $11.45M from $8.76M YoY, driven by clinical development of bosakitug and ATI-052.

Full House Resorts announced its second quarter 2025 results, with consolidated revenues increasing by 0.6% to $73.9 million. The company reported a net loss of $10.4 million, or $(0.29) per diluted common share, compared to a net loss of $8.6 million in the prior-year period. Adjusted EBITDA decreased to $11.1 million from $14.1 million in the second quarter of 2024, primarily due to elevated costs at Chamonix, which was fully operational in the current quarter.

• Consolidated revenues for Q2 2025 increased by 0.6% to $73.9 million compared to $73.5 million in Q2 2024.
• Net loss for Q2 2025 was $10.4 million, or $(0.29) per diluted common share, an increase from $8.6 million in Q2 2024.

BARK, Inc. delivered a solid start to fiscal year 2026, with total revenue exceeding guidance at $102.9 million, despite an 11.5% year-over-year decline. The company significantly improved its net loss to $(7.0) million and achieved positive adjusted EBITDA of $0.1 million, demonstrating progress on profitability and diversification beyond subscription boxes, particularly with strong 49.5% growth in its Commerce segment.

• Total revenue for Q1 FY26 was $102.9 million, surpassing the company's guidance range.
• Net loss improved by $3.0 million year-over-year, reaching $(7.0) million.

Ultralife Corporation reported a challenging second quarter in 2025, with total revenue increasing by 13.0% to $48.6 million due to the Electrochem acquisition. However, GAAP EPS decreased significantly to $0.05 from $0.18 in the prior year, and operating income fell to $2.3 million from $3.9 million, primarily due to a 57.2% decline in Communications Systems sales and pressures on gross profit from product mix, tariffs, and freight costs.

• Total revenue increased by 13.0% to $48.6 million, primarily driven by the inclusion of Electrochem Solutions, Inc.
• GAAP EPS decreased to $0.05, down from $0.18 in the second quarter of 2024, reflecting a challenging period.

Piedmont Lithium reported a net loss of $9.738 million for Q2 2025, with diluted EPS of -$0.44. The company shipped approximately 20,200 dmt of spodumene concentrate, generating $11.9 million in revenue. NAL achieved record production of 58,533 dmt and record lithium recovery and mill utilization rates.

• Piedmont shipped approximately 20,200 dmt of spodumene concentrate, generating $11.9 million in revenue in Q2'25.
• NAL achieved a new quarterly production record of 58,533 dmt of spodumene concentrate, with lithium recovery averaging 73% and mill utilization of 93%.